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ABSTRACT 
 The worldwide impact of vaccines on human health through the prevention of death, 
disease, and suffering caused by infectious disease cannot be overstated. The use of 
inactivated or live-attenuated microbes, as wells as alum or oil-in-water adjuvanted vaccines 
has been successful in limiting or eradicating disease across the world. However, each of 
these existing vaccine formulations carries its own shortcomings and limitations associated 
with their use. These deficiencies will need to be addressed and overcome through the 
identification and development of new vaccine adjuvants and/or delivery platforms. It would 
also be beneficial to those populations of individuals who exhibit increased susceptibility to 
infectious disease or who respond poorly to vaccination to identify adjuvants capable of 
enhancing efficacy in these immunologically deficient groups. While providing for antigen 
delivery, the studies described herein demonstrate that polyanhydride nanoparticles are 
capable activation of innate immune cells, particularly dendritic cell populations, in a manner 
that avoids induction of an overtly proinflammatory environment. These effects are 
associated with improved induction of cytotoxic CD8+ T cell memory, as compared to the 
inflammatory TLR ligand CpG, and resultant decreased tumor progression. The stimulation 
of the STING pathway using cyclic dinucleotides also demonstrated differential activation of 
the innate immune system as compared to TLR ligands. STING mediated stimulation of 
innate immune cells results in a differential activation phenotype that avoids production of 
innate, antimicrobial effector molecules. This led to increased BAFF production which was 
associated with higher vaccine-induced antibody titers in healthy adult mice, as well as in 
aged animals. This is potentially a unique outcome given the fact that aged individuals often 
respond poorly to TLR ligand adjuvanted vaccine formulations. This suggests that by 
xiv 
leveraging pathways and/or materials that avoid undesirable aspects associated with innate 
inflammatory response against microbial infection leads to a more hospitable inflammatory 
environment that results in a better adaptive immune response following vaccination. 
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CHAPTER 1.    GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
Vaccination 
 Since its inception, prophylactic vaccination has proven to be one of the most 
effective and impactful medical strategies to improve human and animal health. Vaccination 
is unique as an intervention in the control of infectious disease as it has the ability to confer 
indirect protection to individuals who did not receive the vaccine through herd immunity [1]. 
Natural infection has long been known to provide long-lived immunity to reinfection 
(assuming you survive). Knowing this, most strategies of vaccination have centered around 
mimicking a state of natural infection, while avoiding onset of disease or illness.  
Early effective vaccine formulations contained attenuated live strains of bacteria or 
virus. These formulations have proven successful in the overall prevention of disease dating 
back to the original Jenner smallpox vaccine of the 18th century [2,3]. This strategy of 
vaccination though successful carries some risk, albeit very low, that the attenuated strain 
may genetically revert to a highly virulent state and cause the very disease it was meant to 
prevent [4]. Inactivated vaccines removed this potential complication but can exhibit lower 
efficacy relatively decreased duration of protection, particularly in populations that tend to 
respond poorly such as the young or aged [5,6]. Highly purified recombinant protein subunit-
based vaccines have also become common as they avoid undesirable reactogenicity caused 
by presence of various microbial components though this further reduces the immunogenicity 
and efficacy [7]. 
In order to improve these responses to inactivated vaccines or recombinant subunit 
vaccines, the inclusion of immune stimulatory adjuvants has become common [8]. The 
16 
mostly commonly used adjuvants in approved vaccine formulations consist of aluminum 
salts, oil-in-water emulsions, and more recently TLR ligands like MPLA [9,10]. While exact 
mechanisms for some of these is largely unknown the overall effect is to induce activation 
and inflammatory responses of the innate immune system via pathogen-mimicking or danger 
signals, comparable to the recognition of bacteria or viruses [11]. In large portions of the 
population these strategies have been successful in inducing efficacious antibody titers, 
though vaccines for disease that require generation of memory cytotoxic CD8+ T cells has 
lagged behind [12]. The best method to induce CMI, aside from naturally occurring infection 
(if you survive), has been to utilize a multiple dose prime-boost strategy which can lead to 
poor patient compliance and longer time required for efficacious immunity to develop [13]. 
New strategies involving the incorporation of various aspects of pathogen mimicking, such 
as various PRRs, have proven to be potent adjuvants in the area of vaccine development 
[14,15]. However, few have led to commercially available FDA licensed products [16]. 
 
Dendritic Cells 
 Dendritic cells were discovered to be potent stimulators of T cells capable of 
processing and presenting antigen in in the context of MHCI and MHCII [17–19]. Dendritic 
cells are divided into three major populations consisting of classical DCs (cDC), monocyte-
derived DCs (moDC), and plasmacytoid DCs (pDC). 
 In mice the, cDC populations consist of CD8α+, CD103+, and CD11b+ 
subpopulations. The cDC family are generally found in barrier tissues and organ points of 
entry. Upon encounter with foreign antigen and/or MAMPs, activation is initiated resulting in 
increased antigen uptake, processing, and presentation on MHCI/MHCII, proinflammatory 
cytokine production, costimulatory molecule upregulation (B7 family molecules), and 
17 
eventual trafficking to draining, secondary lymphoid tissues [20]. The CD8α+ DCs found in 
lymphoid tissues, and CD103+ DCs found in the periphery have been describe to be 
specialized in the cross-presentation of antigens, not normally found in the cytosol, in the 
context of MHCI [21–24]. This activity is critical in the cross-priming induction of CD8+ T 
cell populations [25,26]. The activity of CD11b+ DCs remains somewhat undefined as this is 
a heterogenous population of cells [27]. 
 Plasmacytoid DCs, are a distinct subset of nonclassical dendritic cell with unique 
functional characteristics [28]. Plasmacytoid DCs are found circulating in the blood as well 
as in organ tissues in the periphery [29]. The primary function of pDCs upon activation is 
their ability to secrete large amounts of type 1 IFNs (IFNα, IFNβ) upon activation, primarily 
via TLR7 and TLR9 [29,30]. Despite the expression of MHCI and MHCII and associated 
antigen presentation pDCs, as compared to other DC populations, are relatively poor at 
presenting antigen to CD4+ and CD8+ T cells [31]. Despite poor performance as antigen 
presentation to T cells, pDCs play an important role in response to viral infection by the 
production of type 1 interferons. 
 Another nonclassical population of DCs are the monocyte derived DCs. This 
population commonly arises as a result of infection or inflammation [32]. Monocytes are 
recruited to sites of active inflammation where recognition of MAMPs, and subsequent 
proinflammatory cytokine environment, initiates activation and differentiation of the 
infiltrating monocytes to DCs or macrophages [33,34]. The moDC population shares 
functional similarities to the CD11b+ cDC populations relating to antigen presentation and 
costimulation of T cells [35]. In vitro GM-CSF bone marrow derived DCs (BMDCs) are 
phenotypically the most similar to moDCs allowing them to be modeled in vitro, though the 
18 
exact relation of BMDCs to a singular population of DCs found in vivo remains contested 
[36–38]. 
 
Toll-Like Receptors 
 Toll-like receptors (TLRs) are a family of receptors that are broadly expressed on 
cells of the innate immune system, B cells, as well as mucosal facing epithelial and 
endothelial cells. These receptors recognize a wide variety of microbial or pathogen-
associated molecular patterns (MAMPs/PAMPs). TLRs 1,2,4,5, and 6 are found on the 
surface of innate immune cells and detect extracellular MAMPs consisting of, lipopeptides 
recognized by TLRs 1/2/6/10, endotoxin or lipopolysaccharides (LPS) are recognized by 
TLR4, and flagellins bind to TLR5 [39–42]. Intracellularly expressed TLRs, TLR 3, 7, 8, and 
9 recognize nucleic acid products such as double-stranded RNA which is recognized by 
TLR3, single-stranded RNA binds to TRL7/8, CpG DNA motifs are ligands for TLR9, 
ribosomal RNA is recognized by TLR13, and profilin binds to TLR 11/12 [40,43–46].  
 Upon recognition of their ligands, these TLRs largely signal through the adapter 
molecule myeloid differentiation primary response gene 88 (MyD88), or through TIR 
domain containing adapter inducing interferon-β (TRIF) [47]. These signaling events 
ultimately lead to the activation of innate immune cells and the production and secretion of 
proinflammatory cytokines enhanced by transcription factors including NF-κβ, IRF5, and 
AP-1 [48–50]. This induction of an activated pro-inflammatory state via TLR stimulation 
also results in the production of antimicrobial innate immune effector molecules. This 
includes production of nitric oxide via nitric oxide synthase 2 (NOS2/iNOS), as well as 
reactive oxygen species by DCs and MΦs [51–53]. This recognition of MAMPs is critical in  
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the activation and mobilization of the innate immune system to quickly respond to and 
control an infection while adaptive immunity develops should it be necessary. 
 
 
Figure 1-1. Toll-Like Receptor Signaling. Representative overview of the TLR family of 
receptors, their ligands, and downstream signaling events [54].  
Lim K-H, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol 2013 
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Nitric Oxide 
 Nitric oxide (NO) can be produced by three different isoforms of nitric oxide 
synthase (NOS) enzymes. Neuronal NOS (nNOS/NOS1) expressed in neurons to regulate 
blood pressure and smooth muscles, inducible NOS (iNOS/NOS2 expressed in activated cells 
of innate immune system, and endothelial NOS (eNOS/NOS3) is expressed in endothelial 
cells to control vasodilation and blood pressure [55]. The immunologically associated NOS2 
is a component of the rapid innate immune response to microbial encounter and it is not 
constitutively expressed in resting state innate immune cells, but is transcriptionally 
upregulated upon recognition of MAMPs via activation of NF-κβ [51,56]. Interferon-γ 
(IFNγ) can also induce the expression of NOS2 via activation of JAK/STAT pathway and 
subsequent induction of interferon response factor 1 (IRF-1) [57]. Synergistic effects can also 
be observed on the transcription of NOS2 when IFNγ is combined with TLR stimulation 
[58]. Multiple other transcription factors, including HIF-1, have also been implicated in the 
induction of NOS2 [59]. 
 The NOS2 production of NO in innate immune cells in response to infection plays an 
important role in the clearance of pathogens, as demonstrated by increased susceptibility to 
various infections in NOS2 deficient animals [51,60–63]. This is further supported by the 
fact that some microbes have evolved mechanisms to inhibit and evade NOS activity [64,65]. 
The antimicrobial mechanism ascribed to NO is largely associated with the inhibition of 
DNA synthesis, and breakage of DNA strands as well through formation of peroxynitrite, 
another reactive downstream product of NO, which can nitrosylate and oxidize nucleotides 
[66,67].  
 Despite its role as a potent, rapidly induced antimicrobial mediator, NO production by 
the innate immune system is very much a double-edged sword. The induction of NO has 
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been implicated in numerous deleterious or inhibitory effects on the adaptive immune 
system. T cell activation, proliferation, and effector function is inhibited by NO produced by 
innate immune cells [68–72]. B cells are also vulnerable bystanders to the cytotoxic effects 
of monocyte derived NO leading to depressed antibody responses [73]. A baseline level of 
intrinsic NO does seem to be required for normal function of B and T lymphocytes and 
plasmas cell populations suggesting a source, amount, and context dependent role for NO 
and the outcome of an adaptive immune response to infection or vaccination [74,75]. 
 
Reactive Oxygen Species 
 Reactive oxygen species are a family of innate immune anti-microbial effector 
molecules that also possess second messenger functions in various signaling pathways 
[76,77]. This family consists mainly of anionic superoxide, hydroxyl radicals, hydrogen 
peroxide, and peroxynitrite that can oxidize DNA, lipid, and proteins to interfere with 
microbial biochemical processes [78,79]. The production of ROS occurs in activated innate 
immune cells upon recognition of PAMPs and subsequent production IFNγ and its induction 
and enhancement of ROS production [80–83].  
Reactive oxygen intermediates can be produced by two major potential sources. 
Phagocytic cells express the membrane bound multiprotein electron transferase, NADPH 
oxidase (NOX2), which is a major source ROS in the innate immune system [78]. This 
NOX2 derived ROS in particular has been deemed essential in the innate immune clearance 
of pathogens as illustrated by deficiencies in NOX2 which results chronic granulomatous 
disease (CGD) and the associated susceptibility to infections [84,85]. The mitochondria of a 
cell can also be a key source of ROS production [86]. Recognition of MAMPs via TLR 
ligands, as well as the proinflammatory cytokine IFNγ, lead to the induction of mitochondrial 
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ROS generation through repurposing of mitochondria via Krebs cycle breakage, thought the 
full mechanism is not fully described. [87–89].  
 Despite the critical nature of ROS in clearing pathogens, the production of high 
concentrations is not without drawbacks. Induction of ROS has been linked to inhibition of 
IFNβ production via the STING pathway and decreased functionality of APCs and T cells 
[90–93]. B cell phenotypic differentiation (plasma cell, GC B cell) is also directly affected by 
transcriptional control exerted by ROS [94]. In addition to playing a proinflammatory role 
through the regulation of transcription factors, ROS can cause DNA damage to neighboring 
cells in a paracrine fashion [95]. While high ROS concentrations can exert negative effects 
on immunological function there is also dysfunction associated with abnormally low levels of 
ROS as well [96]. These results, while somewhat conflicting, indicate that the role for ROS 
in immunological function are not fully understood and are likely to be concentration and 
context dependent. 
 
BAFF 
 B cell activation factor (BAFF, also known as TNFSF 13b, BLyS, TALL-1, THANK, 
zTNF4) and its receptor, BAFF-R, are described to display an essential role in the survival of 
B cell populations [97–100]. In particular the B2 B cells, marginal zone and follicular B 
cells, critically rely on BAFF/BAFF-R signaling for maintenance and survival while the 
peripheral innate-like B1 B cells do not [101]. The BAFF-R is expressed on the surface of all 
mature B cells, including memory B cells, but is not present on differentiated short- or long-
lived plasma cells [102,103]. BAFF itself is primarily produced, either secreted or in 
membrane-bound form, by cells of the innate immune system such as MΦs, DCs, monocytes, 
and neutrophils though it can also be produced by T cells and activated B cells [104]. 
23 
 In addition to providing static survival signals to various B cell populations, BAFF 
also plays a major role in supporting the proliferation B cells and subsequent overall outcome 
of adaptive humoral responses [105]. Despite the fact that serum IgG levels are lower in 
BAFF knock-out mice, relative to that observed for wild-type mice, upon immunization, 
there is normal germinal center formation in these mice. Normal germinal center formation is 
also observed in wild type mice when BAFF is inhibited [106]. However, these germinal 
centers are not maintained and dissipate much more rapidly than in BAFF sufficient mice 
which is, at least in part, due to the lack of an effective follicular DC network [107]. T 
independent antibody responses are also impaired when BAFF is not present at normal levels 
though this is directly related to the decreased numbers of B cells and associated proliferation 
rather than germinal center maintenance [101]. 
 While BAFF signaling is critical for the normal development of humoral responses, 
conversely, overexpression of BAFF is associated with the generation of autoimmune 
conditions with the clinical manifestations similar to those of systemic lupus erythematosus 
(SLE) [104]. This partially appears to be caused by the constitutively high concentrations of 
BAFF supporting the survival of autoreactive low-affinity B cells. Some studies have 
suggested that patients with SLE exhibit higher concentrations of BAFF, similar to the 
overexpressing transgenic mice, however, this is controversial [108]. This suggests that 
temporarily high concentrations of BAFF upon immunization may be correlated with 
improved antibody titers, while avoiding the long-term negative effects of autoimmunity. 
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Bacillus anthracis History and Pathogenesis 
Bacillus anthracis is spore-forming, gram-positive bacterium that induces a disease 
whose historical description date to pre-biblical eras. It was not discovered that B. anthracis 
was the causal agent of anthrax, also known as wool sorters disease, until the 1870s 
[109,110]. Cases in textile, and other animal processing industries, dropped greatly after the 
introduction of the Sterne vaccine for livestock [111,112]. The only major outbreaks of 
anthrax in humans, after the introduction of the Sterne vaccine, occurred in 1979 by an 
accidental spore release from a Soviet Union facility. In 2001, the first use of B. anthracis 
spores as a biological weapon, occurred in the United States when spores were dispersed 
through the federal mail system [113,114]. The events in 2001 led to renewed public health 
concern about anthrax as potential weapon of biological warfare that was no longer just a 
weapon of nation states but could be carried out by small groups or individuals [115,116]. 
The major virulence factors of B. anthracis infection are the anthrax toxins (AT). The 
ATs consist of lethal factor (LF), edema factor (EF), and protective antigen (PA). The ATs 
are considering amongst the family of AB toxins, where the A subunit, LF and EF in this 
case, is catalytic component within a target cell, and a B subunit, PA in this case, that binds 
to the cell and facilitates entry of the catalytic A subunit into the cytosol [112]. PA functions 
by binding to its ubiquitously expressed receptors, tumor endothelial marker 8 
(TEM8/ANTXR1), and capillary morphogenesis protein (CMG/ANTXR2), and their 
controversially associated coreceptor lipoprotein receptor-related protein 6 (LRP6) on the 
surface of cells [117–119]. After binding to the cellular surface occurs, the whole PA83 is 
cleaved by a member of the furin family of proteases leaving a free PA20 N terminal subunit 
and a receptor-bound PA63 subunit [120]. This receptor associated PA63 subunit self 
assembles into a heptameric complex known as the prepore. The oligomeric prepore is able 
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to bind three subunits of LF or EF before being endocytosed by the target cell [121]. As the 
pH drops in the endosome, it leads to a conformational change resulting in the heptameric 
pore inserting itself into the endosomal membrane where it can facilitate the entry of LF and 
EF into the cytosol [122,123]. 
Upon translocation into the cytosol, LF cleaves and inactivates the family of mitogen-
activated protein kinase kinases (MEKs). This causes the inactivation of MAPK family 
members JNK, p38, and ERK [124]. This damage leads to apoptotic cell death and 
suppression of the activity of the innate immune system [125]. The second catalytic toxin 
secreted by B. anthracis, EF, is an adenylyl cyclase that converts ATP to cyclic AMP 
(cAMP). This conversion rapidly increases the cellular levels of cAMP, and decreases levels 
of ATP [126]. This increase in cAMP leads to massive fluid secretion and edema of tissues 
and associated organ damage [119]. Together these toxins lead to disarming of the early 
immune response to infection with B. anthracis assisting with widespread bacterial 
dissemination. Lethal factor causes vascular collapse as its primary effects are on 
cardiomyocytes and smooth muscle, while EF results in multi-organ damage and failure 
[112,127,128]. 
The reliance of EF and LF on the pore forming activity of PA to function in the 
pathogenesis of B. anthracis makes it an ideal vaccine antigen candidate as effective PA 
neutralization would block the function both catalytic toxins.  
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Figure 1-2. Protective antigen facilitates Lethal Toxin and Edema Toxin entry into cells. 
An overview of B. anthracis toxin entry into cells [122]. 
Young JAT, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and 
translocation. Annu Rev Biochem 2007 
 
Anthrax Treatments and Practical Considerations 
 With B. anthracis as a major concern for its potential use as an agent of biological 
warfare, current preventative and therapeutic treatment options are far from ideal. Use of 
antibiotics to treat anthrax infection has had success in improving survival after an exposure 
[129,130]. However, due to the resilience of the B. anthracis spore, disease can potentially 
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occur long after the initial exposure, in some cases up to 100 days [131]. This necessitates a 
rigorous long-term regimen of prophylactic antibiotics that can have poor patient adherence 
[132,133]. Such an extensive antibiotic schedule would require large and readily available 
stockpiles of the appropriate drugs ready to distribute immediately upon an exposure event 
[134]. This limits the overall practical effectiveness of antibiotics against B. anthracis 
 Monoclonal antibodies (mAbs) have also been developed to target neutralizing 
epitopes of the B. anthracis PA toxin component. Many of these mAbs have been successful 
in improving survival subsequent to challenge in laboratory animal species [135–137]. 
However, the widespread usage of mAbs would be burdened by similar challenges as 
antibiotics in regards to the production, stockpiling, multiple doses due to antibody half-life, 
and distribution in the event of a large-scale anthrax spore release. 
 This leaves vaccination as a more cost-effective and practical option. That said, 
current anthrax vaccination strategies are not without their own shortcomings. The current 
alum adsorbed AVA BioThrax vaccine requires three doses over the course of six months 
along with regular boosters to maintain efficacy [138]. This makes mass vaccination of a 
large population of potentially exposed people largely impractical as it would take a great 
number of doses, and considering the boosters, far too lengthy a time period until protection 
would be possible. The alum component of the AVA BioThrax vaccine has also been 
implicated in blocking or biasing the humoral response towards non-neutralizing epitopes, 
likely limiting its potential efficacy [139–142]. Long-term shelf stability is also an area of 
concern for the AVA BioThrax vaccine [143,144]. Improvements in storage stability, and 
moving towards single dose efficacy would make vaccination a much practical to prepare for, 
and easier to distribute material for during the event of a large-scale anthrax release. 
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Polyanhydride Particle Platform 
 The primary rationale behind the development and use of polyanhydride nano- or 
microparticle formulations, consisting of the copolymers of the anhydrides 1,6-bis(p-
carboxyphenoxy)hexane (CPH), 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), and 
sebacic acid (SA) as vaccine adjuvants and recombinant antigen delivery vehicles is to 
provide specific aspects of pathogen-mimicking that other adjuvant formulations cannot. The 
use of pattern recognition receptor (PRR) signaling molecules, such as TLRs, or sustained 
inflammatory effects, as with alum or oil-water emulsions, can provide potent innate immune 
recruitment and activation to improve adaptive immune responses to vaccination [9,10,145]. 
 Polyanhydride particle formulations are capable of providing some similar effects to 
the traditional adjuvant formulations, such as inducing activation of DCs and MΦs as 
measured by co-stimulatory molecule upregulation, cytokine production, and antigen 
presentation [146,147]. As opposed to traditional adjuvants, particles also provide other 
aspects of pathogen-mimicking that can improve vaccine responses. These include extended 
payload release kinetics that can mimic the antigen duration of a natural infection, a small 
particulate context for antigen that is comparable to bacteria and viruses, and hydrophobic 
regions that can mimic similar aspects of various pathogens [147–149].  
 In addition to innate immune activating, pathogen-mimicking properties, 
polyanhydride formulations have also demonstrated the ability to provide stability to 
encapsulated antigen [150–153]. This provides a dual benefit for polyanhydride particle-
based formulations, that in addition the inherent adjuvant benefits, that the encapsulated 
antigen can prolong storage times at a variety of temperatures. This would particularly be 
advantageous for recombinant antigens that are particularly prone to degradation at room 
temperature conditions, or where extended storage, in case of an outbreak, would improve 
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the distribution of doses. 
 These characteristics have been harnessed to provide efficacious, single-dose vaccine 
induced immunity to a number of infectious diseases [150,154,155]. Polyanhydride particles 
have also demonstrated the ability to induce CD8 cytotoxic T cell responses in addition to 
antibody [156–158].  Polyanhydride formulations are also unique in the sense the they are 
providing innate immune activation and protective vaccine responses without overt injection 
site inflammation, reactogenicity, or side-effects as is seen with a traditional adjuvant such as 
alum [159,160]. While polyanhydrides exhibit effectiveness as a vaccine adjuvant, the exact 
biological mechanisms underpinning their mode of action remain undefined. Further 
experimentation is necessary to elucidate their mechanism of action and how their strengths 
may be best harnessed to rationally design the vaccine delivery and adjuvant formulations of 
the future. 
 
STING Pathway 
 The stimulator of interferon genes (STING/MPYS/ERIS/TMEM173/MITA) is a 
relatively recently discovered endoplasmic reticulum (ER) anchored protein that was 
discovered to be a key pathway mediator in the TLR independent innate immune recognition 
of double-stranded DNA (dsDNA) [161,162]. Stimulator of interferon genes is 
predominately expressed in macrophages (MΦ), dendritic cells (DC), T cells, as wells 
epithelial and endothelial cells [162,163]. The STING pathway does not directly recognize 
dsDNA, instead it recognizes cyclic dinucelotides (CDNs) either directly secreted from 
bacteria, or generated through the enzymatic activity of cyclic GMP-AMP synthase (cGAS) 
which converts dsDNA into a cyclic dinucleotide [164,165]. STING exists as an inactive 
homodimer on the ER that upon binding of CDNs undergoes conformational changes [166]. 
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This allows STING to bind tank binding kinase 1 (TBK1) and subsequently translocate to 
perinuclear endosomes via the Golgi [167]. There it activates proinflammatory transcription 
factors including IRF3 and NF-κβ [168,169]. In addition to its sensing of cytosolic DNA, 
significant crosstalk between the cGAS-STING and RIG-I-MAVS has been reported 
suggesting that STING is playing a role in the recognition of RNA as well [170].  
 Upon recognition of CDNs, STING signaling in innate immune cells induces the 
production of proinflammatory cytokines, particularly the type 1 interferon, IFNβ, via the 
transcription factors IRF3, IRF7, NF-κβ, STAT6, as well as playing a role in inflammasome 
activation [171–173]. This combination of transcription factors leads to a balanced pattern of 
Th1 (IFNγ, IFNβ, TNFα) vs Th2 responses (IL-4) via IRF3/NF-κβ and STAT6, respectively 
[174]. This balanced cytokine milieu is also accompanied by an activated, yet not fully 
characterized, “mixed” polarization phenotype of antigen presenting cells (APCs) [175,176]. 
The STING pathway is also not an exclusive detector of MAMPs as STING will also 
recognize self dsDNA from damaged cells in the absence of a pathogen, where persistent 
activation can induce auto-inflammation [177–179]. 
 This potentially places STING recognition of DNA in a category more akin to 
“danger-sensing” rather than exclusively pathogen sensing. This leaves much of the effects 
of CDNs on the immune system as yet undescribed particularly as multiple contexts of 
STING activation come to light [176]. Despite a number of unknowns relating to the 
regulation and function of the STING pathway, CDNs have been described to possess potent 
adjuvant properties [180–183]. As a relatively recently discovered DNA sensing pathway 
further characterization will be necessary in order to fully appreciate the exact effects of 
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STING on the innate immune system and the resultant adaptive responses to damage, 
infection, and vaccination. 
 
 
Figure 1-3. STING pathway activation. Diagram of ligands of STING and downstream 
transcription factors as a result of STING activation [184]. 
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic 
DNA sensing. Nat Immunol 2016 
 
Immunometabolism of Macrophages and Dendritic Cells 
 Many decades ago it was originally observed that activated macrophages, as well as 
other immune cells, require certain metabolites upon activation [185–187]. However, the 
metabolism of immune cells is an area of research that, until recent years, was largely left 
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unexplored. The metabolic pathways involved are the glycolytic pathway, the TCA 
(Krebs/citric acid) cycle, the pentose phosphate pathway, fatty acid synthesis, fatty acid 
oxidation, and amino acid pathways. Each of these plays a key role in the providing the 
necessary ATP and molecular building blocks for immune cell function from rapidly 
proliferating T cells to M2 macrophages and everything in between (Reviewed in depth 
[188]). 
 Aerobic glycolysis as a result of innate immune cell activation and its importance to 
functional proinflammatory responses has been studied extensively. The induction of aerobic 
glycolysis as a result of activation, despite its poor efficiency at generating ATP, provides 
critical precursor building blocks for the biosynthesis of cellular products such as cytokines 
[189,190]. In addition to contributing to biosynthesis, a state of aerobic glycolysis can 
improve survival at sites of inflammation, such as a tumor or bacterial infection, where 
immune cells may be forced to compete for nutrients in an environment that is often hypoxic 
[191]. This is contrasted to the wound healing, tolerogenic, or regulatory phenotypes where 
mitochondrial respiration, fed by varying sources such as fatty acids, is the main source of 
ATP to meet energetic demands [188]. 
 Macrophages, depending upon their general activation state and phenotype exhibit 
distinct metabolic demands [192–194]. Upon recognition of TLR ligands and IFNγ, resting 
macrophages assume a proinflammatory or “classically” activated M1 phenotype; in contrast 
exposure to IL-4 and IL-13 can promote an “alternatively” activated or M2 macrophage 
phenotype [195,196]. Activated M1 macrophages exhibit a distinct metabolic phenotype that 
is characterized by high rates of aerobic glycolysis and little to no mitochondrial oxidative 
phosphorylation [197]. This inhibited rate of oxidative phosphorylation also frees up the 
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mitochondrial machinery for repurposing itself to the production of ROS which in addition to 
antimicrobial effects promotes proinflammatory cytokine production [87,198,199]. Another 
key metabolic trait of M1 macrophages is their metabolism of arginine. Activated 
proinflammatory M1 macrophages utilize arginine as a substrate for NOS2 production of 
nitric oxide [200]. 
 
 
Figure 1-4. Arginine metabolism. Overview of the potential fates of arginine [201]. 
Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J 1998 
 
Conversely, activated M2 macrophages utilize arginine to fuel arginase activity that 
promotes down-regulation of NOS2, induction of tissue regeneration, and wound healing 
2 G. Wu and S. M. Morris, Jr.
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Figure 1 Metabolic fates of arginine in mammalian cells
The five enzymes on which the central limbs of the pathways are based include (clockwise from the top) : nitric oxide synthase (NOS), arginine : glycine amidinotransferase, arginase, arginine
decarboxylase and arginyl-tRNA synthetase.
important roles inmany diverse processes, including vasodilation,
immune responses, neurotransmission and adhesion of platelets
and leucocytes [35,36]. The discovery of the novel arginine-
dependent NO pathway has stimulated renewed interest in the
biochemistry, physiology and nutrition of arginine in animals
and humans.
Although arginine synthesis and transport are clearly key
elements in the overall scheme of arginine metabolism, it is the
processes of arginine catabolism (Figure 1) that have attracted
the most interest in recent years. Three of the end-point products
of arginine in Figure 1 are cell-signalling molecules : NO,
glutamate and agmatine. Glutamate, which is also synthesized
from glutamine, proline and branched-chain amino acids and via
transamination, can give rise to yet another cell-signalling
molecule, c-aminobutyric acid (‘GABA’). Although not com-
monly thought of as cell-signalling molecules, polyamines also
can regulate key cellular processes, such as ion channel function
[37]. The recognition that arginine is a precursor for these
distinct types of cell-signalling molecules represents a dramatic
revision of the traditional textbook view of arginine as primarily
a precursor for the synthesis of proteins, urea and creatine.
Arginine itself plays other roles in physiology and metabolism.
Arginyl-tRNA not only is an immediate precursor for protein
synthesis, but is also involved in the post-translational con-
jugation of arginine with the N-termini of proteins bearing N-
terminal aspartate or glutamate, thereby allowing these proteins
to be targeted for degradation by the ubiquitin-dependent
proteolytic pathway [38]. Arginine also acts as an allosteric
activator of N-acetylglutamate synthase, which synthesizes
N-acetylglutamate from glutamate and acetyl-CoA [39]. As N-
acetylglutamate is an essential cofactor for carbamoyl-phosphate
synthase I (CPS I) (Figure 2), a key nzyme in arginine and urea
synthesis, arginine may play a regulatory role in its own
metabolism. Furthermore, arginine can stimulate secretion of
hormones, such as insulin, growth hormone, glucagon and
prolactin [23,40]. Thus regulation of arginine homoeostasis,
which depends on dietary arginine intake, whole-body protein
turnover, arginine synthesis and catabolism, is of considerable
nutritional and physiological significance. In this review, we will
examine current views of arginine metabolism in mammals.
ARGININE SYNTHESIS
The metabolic pathway for arginine synthesis in mammals via
P5C synthetase and proline oxidase is illustrated in Figure 2
[41,42]. Some of the enzymes in this pathway are present in a
variety of cell types, while expression of other enzymes is highly
restricted. Phosphate-dependent glutaminase, ornithine am-
inotransferase (OAT), argininosuccinate synthase (ASS), arg-
ininosuccinate lyase (ASL) and aspartate aminotransferase are
widely distributed in animal tissues [42–45], whereas CPS I,
ornithine carbamoyltransferase (OCT) and N-acetylglutamate
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[202]. Upon activation M2 macrophages also differ in their utilization of metabolic pathways 
to meet energetic demands. M2 macrophages exhibit lower utilization of glycolysis and 
increased mitochondrial oxygen consumption rates as compared to resting or M1 
macrophages [203]. In particular, M2 macrophages critically rely on fatty acid oxidation to 
fuel mitochondrial respiration, as inhibition of these pathways blunts the M2 phenotype 
development and function [203]. 
Dendritic cells exhibit comparable distinct patterns of activation in the context of 
differential metabolic changes. Upon recognition of a MAMP, such as a TLR ligand, 
inflammatory DCs exhibit an immediate upregulation of glycolysis [204,205]. In addition to 
this early glycolytic burst, DCs also exhibit long-term commitment to aerobic glycolysis 
driven by NOS2 activity. Consequently, NOS2 derived NO causes nitrosylation of proteins in 
the electron transport chain, specifically complex I, complex II, and complex IV, blocking 
consumption of oxygen and ATP production via mitochondrial respiration [206–209]. 
Conversely tolerogenic DCs have a metabolic phenotype that has limited commitment to 
glycolysis and high capacity for mitochondrial respiration [210,211]. 
In nearly all cell types of the immune system, metabolism has been inextricably 
linked to functional phenotype. Inhibition of metabolic pathways can directly alter phenotype 
and skew immunological outcomes, a noteworthy example of this is the use or rapamycin to 
blunt glycolysis and CD8+ T cell effector expansion leading to increased memory generation 
[213–219]. While great strides in the understanding of immunometabolism and its role in 
immune function have occurred in recent years, the question of which comes first, the 
metabolism or the functional phenotype remains largely unanswered. What is clear though, is  
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that metabolism is an incredibly sensitive and useful technique to observe activation of 
immune cells in real time, and insight into the functional phenotype of the cells as well. 
 
 
 
Figure 1-5. Dendritic cell metabolism and nitric oxide. Representation of how NO plays a 
role in the induction of aerobic glycolysis in dendritic cells upon TLR stimulated activation 
[212].  
Thwe PM, Amiel E. The role of nitric oxide in metabolic regulation of Dendritic cell immune 
function. Cancer Lett 2018 
 
 
 
expression of these enzymes by a wide vari ty of cell types is now
appreciated [14e17]. Of highest relevance to this review, inducible
NOS (iNOS, NOS2) is the primary NO-synthesizing enzyme
expressed by immune cells and is often not constitutively
expressed but is potently induced during stimulation by inflam-
matory signals [18,19]. All NOS enzymes catalyze the reaction that
converts substrates L-arginine, NADPH, and O2 to L-citrulline,
NADPþ, and NO [19]. As amembrane permeable volatile compound,
NO participates in a variety of cellular processes that can extend
beyond cell-intrinsic impacts on the cells that produce it [20e22].
The NO radical can influence cellular processes through a number
of distinct mechanisms (reviewed in Ref. [20]), including: 1) the
formation of toxic compounds such as superoxide (O2") and per-
oxynitrite (ONOO") [23]; 2) S-nitrosylation of proteins leading to
altered cellular activity [24,25]; 3) deamination of nucleic acids
leading to genetic mutation [26].
Heterogeneity of DC subsets
DCs refer to a broadly heterogeneous family of immune cells
that include cells derived from both myeloid and lymphoid lineage
progenitors (reviewed in Ref. [27]). These cells are specialized in the
their ability to acquire and process antigen, their expression of
MHC-II antigen presentation machinery, their ability to travel to
secondary lymphoid organs after activation, and their capacity to
initiate antigen-specific T cell activation in these compartments
[27]. So called “classical DCs” found in secondary lymphoid organs
can be subdivided into two major subsets: CD11bþ DCs, which are
thought to specialize in cytokine production and CD4þ T cell acti-
vation [28,29]; and CD8þ DCs which specialize in cross-
presentation of exogenous antigen and are potent activators of
CD8þ T cells [30e32]. In addition, there exist a number of non-
classical DC subsets that play an important role in peripheral im-
mune surveillance and infection response. These include the
circulating and ti sue-resident plasmacytoid DCs (pDCs) that are
potent producers of Type I interferons [33,34], skin-resident
Langerhans cells [35,36], and monocyte-derived “inflammatory
DCs” (iDCs) [37e39].With technological advances, different subsets
of cDCs and pDCs in both mouse and human have been newly
identified based on their tissue localization, surface markers, and
ontogeny [40e42]. In the vast majority of in vitro edifferentiated
DC studies in both mouse and human syste s, myeloid precursors
(typically bone-marrow stem cells or circulating monocytes) are
differentiated in the presence of the cytokine GM-CSF (with or
without IL-4) to generate relatively pure populations of DC-like
cells that are thought to most closely resemble iDCs both geneti-
cally and functionally [43,44].
Variability of iNOS expression in DC subsets
In evaluating the physiological role of NO in DC biology, it is
important to note that iNOS is expressed only by specific subsets
of DC populations, whether these be in vivo subsets or in vitro DC
models, and that there exist notable differences in iNOS regula-
tion between mice and humans DCs. Early studies
determined that LPS and IFN-g can induce iNOS expression
in mouse GM-CSF edifferentiated bone marrow-derived DCs
(GM-DCs) [45]. In addition, mouse skin-derived DCs express iNOS
and produce NO in response to LPS [46,47] and a role for NO
production by thymic DCs in T cell differentiation has also been
reported [48]. As originally defined, monocyte-derived iDCs
(originally coined TNF-a/iNOS-producing-DCs, or “TipDCs”) ex-
press iNOS and are potent producers of NO that are required to
control a number of different types of both bacterial and viral
infections [39,49,50]. Nevertheless, unlike infection-associated
iDCs and in vitro ecultivated GM-DCs, classical DC subsets in
secondary lymphoid organs do not readily express iNOS nor
produce detectable amounts of NO [9,51,52]. Conventional GM-
Fig. 1. Model of NO-mediated impacts on DC metabolism and function. Upper right panel, kinetics of NO-dependent and eindependent glycolytic induction are illustrated. Main
figure, the pleiotropic effects of NO on DC metabolism and function are modeled.
P.M. Thwe, E. Amiel / Cancer Letters 412 (2018) 236e242 237
36 
Aging and Immunity 
 Advancements in the biological sciences and medical fields have led to the 
developments and improvement in the prevention and management of countless types of 
illnesses and medical conditions. This has led to overall improved quality of life and 
longevity [220,221]. This increase in lifespan is not entirely mirrored by equivalent increases 
in healthspan, or years without major health issues affecting quality of life. The underlying 
effects of aging and age-related disease means that a greater number of individuals are at risk 
for complications related to the aging process itself [222]. One of the more concerning 
dysfunctions that arises with advanced age is immunosenescence and the associated chronic 
low-level inflammation of the innate immune system known as “inflammaging” [223].  
 In advanced age, the innate immune system is profoundly altered. Neutrophils have 
blunted chemotactic ability, which is thought to contribute to sustained local inflammation, 
as well as decreased ability to phagocytose opsonized particulates, though interestingly not 
un-opsonized particles [224–226]. Neutrophil cytokine signaling, as well as the production of 
innate effector molecules such as NO and ROS is also reduced, leading to diminished ability 
to clear pathogens [227]. Macrophages and DCs exhibit diminished phagocytosis, decreased 
antigen processing/presentation, lower costimulatory molecule expression, as well as 
diminished cytokine secretion and responsiveness upon recognition of MAMPs, particularly 
the TLR PRRs [228–231]. This hyporesponsiveness of APCs has been linked to the poor 
activation of CD4+ and CD8+ T cells [232–234]. Myeloid derived suppressor cells have also 
been shown to increase in relative number in aged population potentially contributing to poor 
development of adaptive immunity [235]. Whether these deficiencies are due to decreased 
receptor expression or signaling defects is contested, leaving the opportunity to identify 
pathways that may be less affected by aging or create an inflammatory environment that is 
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more conducive to the generation of adaptive immune responses. 
 The adaptive immune system is also impacted by advanced age. Aged individuals 
have decreased numbers of circulating B cells as well as a narrowed repertoire of available 
naïve B cells in lymphoid tissues [236,237]. B cells from the aged also display decreased 
activation-induced cytidine deaminase (AID) activity, the key enzyme of somatic 
hypermutation and class switching of the B cell receptor, which in turn leads to decreased 
generation of high affinity antibodies [238,239]. Similar to B cells, naïve T cells are also 
present in decreased number in lymphoid tissues [240]. These naïve T cells also represent a 
limited repertoire of TCR specificities [241]. These numerous age-induced immunological 
disadvantages lead to worse health outcomes from infections and poor efficacy of vaccines 
[242,243]. This highlights a need to develop more effective vaccination strategies that are 
capable of navigating the complications of immunosenescense and inflammaging to provide 
protection from the inherent age-related susceptibility to infectious disease. 
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Abstract 
A need exists for new and effective immunotherapies capable of activating cell-
mediated adaptive immunity and eliminating malignancies when administered in conjunction 
with chemotherapeutic, surgical, and checkpoint blockade interventions. Such approaches 
require immunization regimens that appropriately activate antigen-presenting cells, most 
notably dendritic cells, to induce efficacious cell-mediated immunity directed toward tumor-
specific or pathogen associated antigens. In this regard, micro- and nanoparticles formulated 
from polyanhydride copolymers represent a candidate platform for immunotherapy, as they 
can be effectively internalized by and activate dendritic cells in vitro. In this study, 
polyanhydride nanoparticles induced activation and upregulation of costimulatory molecules 
on various dendritic cell populations in vitro, most notably CD8a+ DCs. However, 
nanoparticle-activated DCs did not induce/secrete large amounts of pro-inflammatory 
cytokines (e.g., TNF), chemokines (e.g., CXCL9, CXCL10), drive characteristic metabolic 
changes of activation or induce production of innate antimicrobial effector molecules, such 
as nitric oxide. Using an in vivo tumor model system where protection is restricted to CD8+ T 
cells, a single-dose, prophylactic polyanhydride-based nanovaccine encapsulating a model 
tumor antigen (e.g., ovalbumin) induced a protective CD8+ T cell memory response, 
decreased tumor progression, and increased time on study for mice that received it. Together, 
these results suggest that the use of a polyanhydride-based nanovaccine platform can be an 
effective approach to inducing antigen-specific CD8+ T cell memory and preventing tumor 
progression by providing antigen delivery and DC activation while avoiding the overtly 
inflammatory and immunologically inhibitory responses commonly associated with 
adjuvants. 
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1. Introduction 
Cytotoxic CD8+ T cells are critical mediators of immunological protection against 
tumors and intracellular pathogens [1]. Although naturally-occurring infections are often 
effective at inducing long-lived CD8+ T cell memory, commonly used adjuvants such as 
alum, oil-in-water emulsions or innate immune stimulating Toll-like receptor (TLR) ligands 
have not proven as successful for the induction of cell-mediated immunity (CMI) [2]. Many 
efficacious immunization strategies that induce rapid and robust/durable memory CD8+ T 
cell responses have either employed a multiple dose regimen (i.e., prime-boost) or treated 
animals with adoptively transferred DCs pulsed in vitro with antigen [3–5]. Research 
indicates that DC vaccines capable of generating a large number of memory CD8+ T cell 
populations in a single administration possess the relatively unique property of enhancing 
both antigen presentation and co-stimulation without inducing the overt inflammatory 
response that often results when using more standard antigen-adjuvant combinations [4]. 
Many adjuvants are incorporated into vaccine formulations to induce inflammation and 
innate immune activation to facilitate induction of long-lived antibody titers to vaccine 
antigens [2]. Indeed, adjuvant-associated inflammation has been demonstrated to interfere 
not only with the ability of DC vaccination to induce CD8+ T cell memory, but also impair 
effector CD8+ T cell trafficking and function [4,6]. These blunted responses lead to 
decreased immunotherapeutic efficacy when administered to tumor-bearing mice [4,6]. 
Another common class of adjuvants, TLR agonists, not only induce overt inflammation, but 
also cause production of innate immune effector molecules such as nitric oxide (NO) [7]. 
Nitric oxide in particular has been described to cause deleterious effects on DC activation via 
altered metabolism, decreased survival and impaired co-stimulatory upregulation [8–10]. 
Although effective, the use of low inflammatory DC vaccines also comes with increased 
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costs and the challenges associated with the personalized nature of generating ex vivo DC 
populations to be used therapeutically [11]. Consequently, identification and development of 
novel low inflammatory vaccine adjuvants and antigen delivery systems would be beneficial 
to provide DC vaccine-like outcomes in a more accessible format. 
To improve a vaccine formulation’s ability to induce optimal cytotoxic CD8+ T cell 
memory, novel immune stimulatory strategies and antigen delivery systems that mimic the 
beneficial effects of DC vaccination could be used. Polyanhydride particle-based vaccines in 
particular represent a unique alternative to existing vaccines that employ more traditional 
adjuvants. Nanoparticles consisting of combinations of sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy) hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctante (CPTEG) 
are readily phagocytosed by DCs and provide activation as measured by cytokine and 
costimulatory molecule upregulation [12]. Following administration in vivo, these 
polyanhydride formulations are also known to persist in the local tissues, thus, facilitating the 
controlled release of their encapsulated payload [13,14]. When delivered subcutaneously, 
polyanhydride NPs induce a mild inflammatory response with no evidence of adverse 
histopathological reactions [13,15]. Previous studies have also illustrated the ability of 
polyanhydride formulations to prophylactically enhance CD8+ T cell memory responses and 
elicit protection in a tumor challenge model. However, the addition of a TLR ligand such as 
CpG oligodeoxynucleotides (ODN) to the polyanhydride platform decreased vaccine 
effectiveness indicating that traditional adjuvants may be deleterious to generating CD8 T 
cell memory responses [16,17]. Considering the unique innate immune stimulatory properties 
of polyanhydride NPs, the ability of this platform to activate DCs and induce an effective 
memory CD8+ T cells was tested and compared to the inflammatory TLR agonist CpG ODN, 
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by using an antigen-specific tumor challenge model where protection is restricted to 
MHCI/CD8+ T cell-mediated immune responses. 
 
2. Materials and Methods 
2.1 Synthesis Materials 
Chemicals used for the polymer and nanoparticles synthesis: 4-p-hydroxybenzoic acid, tri-
ethylene-glycol, 1,6- dibromohexane were obtained from Sigma Aldrich (St. Louis, MO); 
dimethyl formamide, acetic acid, acetonitrile, acetic anhydride, toluene, methylene chloride, 
pentane were purchased from Fisher Scientific (Fairlawn, NJ) and 4-p-flourobenzonitrile was 
purchased from Apollo Scientific (Cheshire, UK). 
 
2.2 Polyanhydride Copolymer Synthesis 
Monomers of CPTEG and CPH were used to synthesize a 20:80 CPTEG:CPH 
copolymer via melt polycondensation reaction as previously described [18]. The purity and 
molecular weight of the copolymer was characterized using 1H nuclear magnetic resonance 
spectroscopy in deuterated chloroform. The molecular weight of the copolymer was about 
5.3 kDa, consistent with previous work [19]. 
 
2.3 Nanoparticle Synthesis 
20:80 CPTEG:CPH nanoparticles encapsulating 5 wt.% ovalbumin (Ova) were 
synthesized using flash nanoprecipitation as previously described [20]. Briefly, a solution of 
20:80 CPTEG:CPH and ovalbumin in methylene chloride at a concentration of 20 mg/mL 
was poured into pentane at a solvent to anti-solvent ratio of 1:250. The nanoparticles were 
then collected using vacuum filtration. The particle morphology and size were examined 
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using scanning electron microscopy. The average particle size of nanoparticles used for these 
studies was about 200 nm. 
 
2.4 Animals 
Female BALB/c mice, aged six to eight weeks, were obtained from Charles River 
Laboratories (Wilmington, MA) for in vitro studies. Female C57BL/6 mice, aged six to eight 
weeks, were obtained from Charles River and Envigo (Somerset, NJ). Studies involving the 
use of mice were conducted in accordance with Iowa State University guidelines for the care 
and use of animals and upon approval of the Institutional Animal Care and Use Committee. 
 
2.5 Cell Culture 
The E.G7-OVA (ATCC, Manassas, VA) cell line was cultured and maintained in 
RPMI 1640 (Cat #10-040-CM, Corning) medium containing 2 mM L-glutamine 1.5 g/L 
sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, 0.05 mM 2-
mercaptoethanol, 0.4 mg/mL G418 (Cat #30-234-CI, Cellgro), 100 U/mL penicillin, 100 
µg/mL streptomycin,  and 10 % fetal bovine serum. The EL4 (ATCC) cell line was culture 
and maintained in DMEM (Cat #15-013-CV, Corning) supplemented with 2 mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 10 % horse serum. 
 
2.6 Bone Marrow DC Generation 
Naïve female BALB/c mice were used to generate BMDC cultures. Bone marrow 
was collected from femurs and tibias. Cells were washed and plated in RPMI 1640 medium 
supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin, 2 mM glutamine, and 
10 % FBS in 100 mm petri plates, at a density of 4 x 106 cells per plate with 10 mL of 
64 
medium supplemented with GM-CSF (Peprotech, Rocky Hill, NJ) at 10 ng/ml.  On day three 
of culture, 10 mL of GM-CSF containing medium was added.  On days six and eight of 
culture, 10 mL of culture medium was exchanged for fresh GM-CSF containing medium.  
DCs were harvested on day 10 of culture by gently rinsing and collecting non-adherent cells.  
 
2.7 Splenic DC Isolation 
Naïve female BALB/c mice were sacrificed to collect spleens. Spleens from eight to 
ten mice were harvested, pooled, and homogenized into a population of single cells. Using 
these splenocytes, a highly enriched populations of DCs were recovered using a pan-DC 
isolation kit (13-100-875) (Miltenyi Biotec, Auburn, CA) on an autoMACS Pro separator 
(Miltenyi Biotec) according to manufacturer’s protocol.   
 
2.8 BMDC and sDC stimulation 
DCs were plated at 5 x 105 cells/well in a 96-well round bottom tissue culture plate in 
200 µL of RPMI 1640 medium supplemented with 100 U/mL penicillin and 100 µg/mL 
streptomycin, 2 mM glutamine, and 10 % FBS. Stimulations consisted of 100 µg/well of 
20:80 CPTEG:CPH NPs encapsulating 5 µg of Ova, 5 µg/mL of CpG ODN 1668 (Cat 
#16E17-MM InvivoGen) with 5 µg Ova, or non-stimulated control wells. Stimulations were 
carried out for 48 hours after which supernatants and cells were harvested for cytokine 
analysis and cell surface maker expression by flow cytometry. 
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2.9 Nitric Oxide Quantification 
Supernatants from stimulated DCs were analyzed for nitric oxide indirectly via nitrite 
concentration by Griess assay. A standard curve was created using two-fold dilutions of 
sodium nitrite ranging from 100 µM to 0 µM. 100 µL of supernatant was incubated with 100 
µL of Griess reagents (Cat. No. 03553, Sigma-Aldrich) in a 96 well microtiter plate. Samples 
were incubated for 15 minutes at room temperature and read at 540 nm on a SpectraMAX 
190 (Molecular Devices, Sunnyvale, CA). 
 
2.10 Extracellular Flux Analysis 
BMDCs were stimulated in in RPMI 1640 medium supplemented with 100 U/mL 
penicillin and 100 µg/mL streptomycin, 2 mM glutamine, and 10 % FBS for 18 hours with 
100 µg of 20:80 CPTEG:CPH encapsulating 5 µg of Ova, 5 µg/mL of CpG ODN with 5 µg 
Ova, or no stimulation control in 5 mL polypropylene tubes. Treated BMDCs were washed 
with Seahorse assay media consisting of Agilent Seahorse XF Base medium (Cat #102353, 
Agilent, Santa Clara, CA) supplemented with 1mM sodium pyruvate, 2 mM L-glutamine, 
and 10 mM glucose with a pH adjusted to 7.4, were seeded into 24 well seahorse plates 
coated with Cell-Tak (Corning, Corning NY) at a density of 2.5 x 105 cells per well. 
Metabolic phenotyping was conducted on a Seahorse XFe24 (Agilent). Mitochondrial 
function was analyzed via mitochondrial stress test according to manufacturer specifications 
[21].  Final concentrations of 1 µM oligomycin, 2 µM FCCP, and 0.5 µM rotenone and 
antimycin were used (Agilent) and prepared in Seahorse assay medium. 
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2.11 Murine Vaccination  
For the high antigen dose study (Figure 2-1) (2.0 mg Ova), female C57BL/6 mice 
were vaccinated with formulations consisting of 250 µg Ova encapsulated in 5 mg of 20:80 
CPTEG:CPH (5 % loaded) plus 1.75 mg Ova soluble (NP), 2 mg soluble Ova (sOva), or 
unvaccinated control. In the prime-boost experiment (Figure 2-2) the mice were vaccinated 
with formulations consisting of 1.75 mg soluble Ova along with 5 mg of 20:80 CPTEG:CPH 
polyanhydride nanoparticles encapsulating 250 µg Ova with and without a boost (NPx1, 
NPx2), 2 mg soluble Ova with 5 mg of blank 20:80 CPTEG:CPH polyanhydride 
nanoparticles (Blank NP x2), or PBS control. Mice that received a booster (indicated by x2) 
were given the same formulations at half the original dose of antigen and particle mass. In 
the low antigen dose study (Figure 2-5), mice were vaccinated with formulations consisting 
of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride nanoparticles 
encapsulating 25 µg Ova (NP), 100 µg soluble Ova (sOva), or PBS control. In the multi-
adjuvant experiment (Figure 2-6) mice received formulations consisting of 75 µg soluble 
Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 25 µg 
Ova (NP), 100 µg soluble Ova adjuvanted with 20 µg CpG ODN 1668 (CpG), a combination 
of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride nanoparticles 
encapsulating 25 µg Ova adjuvanted with 20 µg CpG ODN (NP+CpG), or PBS control. All 
formulations were delivered subcutaneously at the nape of the neck. 
 
2.12 Tumor Challenge 
C57BL/6 mice were challenged subcutaneously on the flank with 2-5 x 106 E.G7 Ova 
expressing lymphoma cells or 2.5 x 106 EL4 lymphoma cells and washed and suspended in 
PBS respectively. Tumor growth was monitored three times a week and volumes were 
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calculated by the volume of an ellipsoid. Mice were removed from study when tumor volume 
surpassed 1000 mm3. 
Tumor Volume = (4/3)π r1r2r3 
 
2.13 Cytokine and Chemokine Analysis 
Cytokine quantification was performed using supernatants from the previously 
described DC stimulations. A Millipore Milliplex cytokine/chemokine panel (MCYTOMAG-
70K-32, Burlington, MA) was used to detect cytokines and analyzed on a Bio-Plex 200 
System (Bio-Rad, Hercules, CA) according to manufacturer’s specifications. 
 
2.14 Flow Cytometry 
Splenic DCs and BMDCs were analyzed for costimulatory marker expression using 
flow cytometry. 5 x 105 DCs were aspirated from a 96 well plate and transferred to FACS 
tubes. Prior to labeling with specific monoclonal antibodies, Fc receptors on DCs were 
blocked to prevent non-specific antibody binding by incubating the cells with 100 µg/mL of 
rat IgG (Sigma Aldrich) and 10 µg/mL of anti-CD16/32 (eBioscience, San Diego, CA). 
Subsequently, DCs were stained with fluorescently conjugated antibodies for CD80 
(Biolegend, San Diego, CA, PerCP-Cy5.5, clone 16-10A1), CD86 (eBioscience, FITC, clone 
GL1), CD40 (eBioscience, APC, clone 1C10), CD11c (Biolegend, APC-Cy7, clone N418), 
MHCII (eBioscience, AF700, clone M5/114.15.2), and CD8a (Biolegend, BV421, clone 53-
67) diluted in FACS buffer. Samples were fixed using BD stabilizing fixative (BD 
Bioscience, Franklin Lakes, NJ). Mitochondrial superoxide production was evaluated using 
live cells stained with MitoSOX Red (Cat # M36008, Invitrogen, Carlsbad, CA) according to 
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manufacturer’s specifications. All data was collected on a FACSCanto II (BD Bioscience, 
Franklin Lakes, NJ). Data was analyzed using FlowJo (FlowJo LLC, Ashland, OR). 
 
2.15 Serum IgG detection 
Where applicable, immunized mice were bled via saphenous vein 5 weeks post-
immunization. Anti-Ova serum IgG titers were measured via indirect ELISA. Costar 3590 
96-well EIA/RIA high binding plates (Corning) were coated with 100 µL of Ova (5 µg/mL 
PBS) or PA (0.5 µg/mL PBS) and incubated overnight at 4o C. Plates were blocked using 2.5 
% (w/v) powdered skim milk PBS containing 0.05 % Tween-20 (PBS-T), that has been heat 
inactivated at 56o C for hours to inactivate any phosphatase activity, for two hours at room 
temperature. After three washes using PBS-T, serum samples were titrated across the plate 
using two-fold serial dilutions, starting at 1:100, in PBS-T and 1 % (v/v) normal goat serum.  
Samples were incubated overnight at 4° C. After three washes in PBS-T, an alkaline 
phosphatase conjugated goat anti-mouse IgG (H+L) secondary detection antibody (Cat# 115-
005-003, Jackson ImmunoResearch, West Grove, PA) was diluted 1:1000 in PBS-T and 
added to the wells and allowed to incubate at room temperature for two hours. Plates were 
washed three times with PBS-T and alkaline phosphatase substrate was added at 1 mg/mL in 
buffer containing 50 mM sodium carbonate, 2 mM magnesium chloride, and sodium 
bicarbonate was titrated into the solution in order to achieve a pH of 9.3. Plates were allowed 
to develop for 30 minutes and analyzed using the SpectraMAX 190 at a wavelength of 405 
nm. 
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2.16 Statistical Analysis 
Data generated during flow cytometry assays, metabolic assays, Griess assays, and 
tumor volume experiments were analyzed via one-way ANOVA with a Tukey, Dunnett, or 
Sidak post-test for multiple comparisons. Survival data were analyzed using a log-rank  
(Mantel-Cox) test with a Bonferroni correction for multiple comparisons. All analyses were 
performed using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA). 
 
3. Results 
3.1 High antigen dose polyanhydride nanoparticle vaccination reduced tumor burden 
and increased time on study 
Previous studies from our lab have shown that immunization with high dose (i.e., 2 
mg) of Ova antigen in a polyanhydride particle-based vaccine regimen induced transgenic 
OTI CD8+ T cell memory and the ability to expand these CD8+ T cells upon reencounter with 
antigen [18]. Here, the ability of polyanhydride nanoparticles to induce efficacious 
endogenous antigen-specific CD8+ T cell memory and subsequent effector expansion upon 
challenge was evaluated. C57BL/6 mice were vaccinated prophylactically with high antigen 
dose (2.0 mg Ova) formulations consisting of polyanhydride nanoparticles (NP), sOva alone, 
or a PBS control. Six weeks later, mice were challenged with the subcutaneous implantation 
of Ova-expressing E.G7 tumor cells and tumor progression was tracked. Vaccination with the 
NP formulation significantly reduced tumor progression as measured on day 19 post-
challenge in comparison to naïve control mice, while the unadjuvanted sOva formulation did 
not inhibit tumor progression (Figure 2-1a-b). NP vaccination also significantly improved 
time on study (i.e., % of mice with tumors < 1000 mm3) compared to control animals (Figure 
2-1c). No significant improvements in survival were observed for mice receiving sOva alone 
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compared to controls. To determine whether antigen-specific immune activation was 
responsible for the observed anti-tumor responses, another set of mice was challenged with 
the EL4 parent tumor that does not express Ova. Tumor volume was evaluated 12 days post-
challenge; neither the mice receiving the NP formulation or sOva experienced a significant 
decrease in tumor burden compared to naive control mice (Supplemental Figure 2-8a-b). 
Additionally, neither immunization regimen provided a significant increase in time on study 
(Supplemental Figure 2-8c). Together, these data demonstrate that the NP formulation is able 
to induce efficacious antigen-specific CD8+ T cell memory capable of responding to re-
exposure to antigen (i.e., tumor implantation) 
 
  
 
Figure 2-1. Polyanhydride nanoparticles enhance CD8+ T cell memory generation with 
high dose antigen. C57BL/6 female mice (n=12) were immunized subcutaneously with 
formulations consisting of 1.75 mg soluble Ova plus 5 mg of 20:80 CPTEG:CPH 
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polyanhydride nanoparticles encapsulating 250 µg Ova (NP); 2 mg soluble Ova (sOva); or 
PBS (control). Mice were challenged subcutaneously in the flank with E.G7 Ova expressing 
tumor cells 40 days post-immunization and (a) tumor volume of individual mice was tracked. 
(b) Tumor volume was compared when the first mouse was removed from study on day 19. 
Treatment groups were compared to PBS control using an ordinary one-way ANOVA with a 
Dunnett’s multiple comparison test. Significance is indicated as follows *p ≤ 0.05. Bar 
graphs indicate the group mean ± SEM. (c) Survival was evaluated 30 days post-challenge. 
Significance from PBS control was determined using a Log-rank (Mantel-Cox) test with a 
Bonferroni correction for multiple (2) comparisons. Significance from control is indicated in 
the group legend as follows * p ≤ 0.025. Median survival of each group is also reported. 
 
3.2 Encapsulation of antigen in polyanhydride NPs was critical for inducing optimal 
CD8+ T cell memory 
 Even though our high antigen dose (2.0 mg Ova) vaccine formulation contained a 
large mass of unencapsulated soluble antigen (1.75 mg), we hypothesized that the portion of 
antigen encapsulated within the polyanhydride NPs would be more important to the induction 
of CD8+ T cell memory than the soluble bolus. This hypothesis was tested by vaccinating 
C57BL/6 mice with a single-dose NP formulation, a prime-boost of the same NP 
formulation, a prime-boost of blank NPs with no encapsulated antigen (i.e., soluble Ova 
only), or injecting PBS alone (i.e., control). Six weeks after their last immunization, all mice 
were challenged subcutaneously with the Ova-expressing E.G7 tumor, and the tumor 
progression and time on study for each treatment compared (Figure 2-2a-b). The only 
treatments that significantly inhibited tumor progression compared to PBS injections were 
the single-dose NP and the prime-boost NP regimens. Mice immunized twice with blank NPs 
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plus sOva tended to have an improved median survival time compared to naïve control mice; 
however, this difference was not significant. 
 
 
Figure 2-2. Encapsulated antigen is crucial to induce antigen-specific CD8+ T cell 
memory. C57BL/6 female mice were immunized subcutaneously at the base of the neck with 
formulations consisting of 1.75 mg soluble Ova with 5 mg of 20:80 CPTEG:CPH 
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polyanhydride nanoparticles encapsulating 250 µg Ova with and without a boost (NPx1, 
NPx2) (n=16); 2 mg soluble Ova with 5 mg of blank 20:80 CPTEG:CPH polyanhydride 
nanoparticles (Blank NP x2) (n=8); or PBS control (n=16). Mice that received a booster 
(indicated by x2) were given the same formulations at half the original dose subcutaneously 
at the base of the neck 28 days after the primary immunization. Mice were challenged 
subcutaneously in the flank with E.G7 Ova expressing tumor cells 42 days after the primary 
or boost immunization, respectively and (a) tumor volume of individual mice was tracked. 
(b) Survival was evaluated 31 days post-challenge. Significance was determined using a 
Log-rank (Mantel-Cox) test with a Bonferroni correction for multiple (6) comparisons. 
Significance from control is indicated in the legend as *p ≤ 0.0083. Median survival of each 
group is also reported. 
 
3.3 Polyanhydride NPs upregulated costimulatory molecule expression on DCs but only 
induced low levels of inflammatory cytokine and chemokine production. 
Previous work on polyanhydride particle formulations illustrated that bone marrow-
derived dendritic cells (BMDCs) readily take up and respond to these particles by 
upregulating co-stimulatory molecules and cytokine secretion similar to other pathogen 
mimicking moieties [12,14,22]. The low inflammatory response induced by polyanhydride 
NPs is similar to that induced by DC vaccination as it relates to the induction of CD8+ T cell 
memory [15]. Herein, the ability of the 20:80 CPTEG:CPH polyanhydride NP formulation to 
activate BMDC was compared to the effects of CpG ODN. After 48 hours of in vitro 
stimulation with NPs or CpG ODN, BMDCs respond by upregulating the co-stimulatory 
molecules CD86 and CD40 as compared to non-stimulated control BMDCs (Figure 2-3a) 
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indicating that both stimulants activated the BMDCs and increased co-stimulatory molecule 
expression. Supernatants from stimulated BMDCs were also evaluated for induction of 
inflammatory cytokine and chemokine production. Other than MIP2, KC and IL-6, the NP 
formulation induced markedly less inflammatory cytokine secretion when compared to that 
induced by CpG ODN (Supplemental Figure 2-9a-c). 
 Dendritic cell populations isolated from the spleens of naïve mice were also evaluated 
for their response to stimulation. Splenic DCs (sDC) were stimulated with either the NP 
formulation or CpG ODN for 48 hours; control sDC were not stimulated. The CD11c+ 
population of the sDC was evaluated for upregulation of the costimulatory molecules CD86 
and CD40. The NP formulation upregulated CD86 and CD40 expression while CpG ODN 
only upregulated CD40 as compared to non-stimulated control sDC (Figure 2-3b). The sDC 
CD8a+ subpopulation has been previously reported to cross prime CD8+ T cells [4,23–25]. 
To determine if NP stimulation had any effect on the activation of this population of sDC, we 
measured co-stimulatory marker expression on CD8a+ sDC. CpG ODN induced only a 
moderate upregulation of co-stimulatory molecules on CD8a+ sDC; however, NP stimulation 
induced a marked increase in the expression of CD86, CD80, and CD40 (Fig. 2-3c). These 
findings suggest that NPs are capable of activating a critically important DC subtype 
involved in the presentation of antigen to and activation of CD8+ T cells. Supernatants from 
total population of stimulated sDC were also evaluated for cytokine production via a 
multiplex assay. As observed for the BMDC, a lower magnitude of inflammatory cytokine 
and chemokine responses were observed for NP stimulated sDC compared to those induced 
by CpG ODN (Supplemental Figure 2-10.) 
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Figure 2-3. Polyanhydride nanoparticles activated BMDCs and splenic DC populations. 
Dendritic cells isolated or generated from naïve BALB/c mice were stimulated for 48 hours 
with 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating Ova (5% w/w) (NP); 
CpG ODN plus Ova (CpG); or unstimulated control as described in materials and methods 
section. (a) BMDCs gated on MHCII+ and CD11c+, (b) the total MHCII+ and CD11c+ 
population of DCs isolated from the spleens, and (c) the CD8α+ subpopulation of splenic 
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DCs was analyzed for costimulatory expression via flow cytometry. Significance was 
determined via one-way ANOVA with a Tukey multiple comparison test. P value is indicated 
as follows *p ≤ 0.05. All graphs represent the treatment average ± SEM. 
 
3.4 Polyanhydride nanoparticles activated BMDCs without inducing innate effector 
molecules or altering cellular metabolism 
Upon natural infection or after stimulation with TLR ligands such as CpG ODN, 
activated APCs produce innate effector molecules such as nitric oxide (NO) or reactive 
oxygen species (ROS). Although these molecules provide critical microbicidal activity 
during acute infections [26,27], NO and ROS can also have inhibitory effects on innate 
[8,10,28] and adaptive immune responses [10,29–32]. After 48 hours of in vitro stimulation, 
NO production by BMDC was measured indirectly by assessing nitrite content in 
supernatants. Unlike CpG ODN, which induced high concentrations of NO, stimulation of 
BMDCs with polyanhydride NPs did not result in significant amounts of NO (Fig. 2-4a). 
Lower concentrations of mitochondrial superoxide (mROS) were also observed following NP 
stimulation compared to CpG ODN treatment (Supplemental Figure 2-11). 
After encountering TLR ligands, murine BMDCs exhibit a profound metabolic shift 
away from mitochondrial oxidative phosphorylation and towards sustained aerobic glycolysis 
[33]. This extended commitment to aerobic glycolysis is a consequence of the concentration 
of the innate effector molecule NO; yet, NO plays an important antimicrobial role during 
acute infections and in response to TLR-stimulation [8,9,34]. Because polyanhydride 
nanoparticles were observed to activate BMDC without inducing NO, we hypothesized that 
NP stimulation would result in an BMDC activation phenotype that maintained functional 
mitochondria. After an 18-hour stimulation with NP or CpG, a mitochondrial stress test 
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(MST) was performed on BMDCs and revealed marked differences in metabolic states. CpG 
ODN stimulation resulted in the expected inhibition of ATP production, loss of spare 
respiratory capacity, and increased proton leak (Figure 2-4a-b). In contrast, NP stimulation of 
BMDCs resulted in an overall maintenance of mitochondrial functionality resembling that of 
non-stimulated BMDCs (Figure 2-4a-b). During the MST, the extracellular acidification rate 
(ECAR) was also measured as an indicator of glycolysis. As expected, the CpG ODN 
stimulated BMDCs exhibited an elevated glycolytic rate while NP stimulated cells did not 
(Supplemental Figure 2-12). Together, these results demonstrate that polyanhydride 
nanoparticles, while inducing effective dendritic cell activation, are resulting in a distinctly 
less overt activation phenotype that avoid production of innate effector molecules and 
consequently avoids reliance on aerobic glycolysis. 
 
 
Figure 2-4. Polyanhydride nanoparticles induce a differential metabolic profile of 
activation and no induction of innate effector molecules. 
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Figure 2-4 Continued 
 
BMDCs were stimulated with either NPs, CpG ODN, or control as described in 
materials and methods. (a) Nitric oxide production was measure indirectly via Griess assay 
as nitrite concentration in the cell supernatant 48 hours after stimulation. BMDCs generated 
from BALB/c mice were stimulated for 18 hours with, CpG ODN, or non-stimulated control. 
Stimulated BMDCs were seeded into 24 well seahorse plates coated with Cell-Tak at a 
density of 2.5 x 105 cells per well and a mitochondrial stress test (MST) was conducted. (b) 
Kinetic results of the MST oxygen consumption rate (OCR) are shown along with (c) ATP 
production, proton leak, maximal respiratory capacity, and spare respiratory capacity 
calculated from the MST. Significance between treatments was determined via one-way 
ANOVA with a Tukey posttest. P value is indicated as *p ≤ 0.05. All bar graphs and symbols 
represent the treatment average ± SEM. 
 
3.5 Low antigen dose polyanhydride nanoparticle vaccination reduced tumor burden 
and increased time on study 
 Although high doses of antigen and polyanhydride nanoparticles were effective at 
inducing CD8+ T cell memory upon vaccination, experiments were designed to determine 
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whether lower doses of both Ova and polymer particles could also induce an efficacious 
immune response. A lower dose of Ova (100 µg) and nanoparticle amount (500 µg) were 
administered to mice and the induction of antigen-specific CD8+ T memory was evaluated. 
C57BL/6 mice were vaccinated prophylactically with formulations consisting of the 
polyanhydride nanoparticles (NP-Ova), sOva alone, or a PBS control. Six weeks later, mice 
were challenged subcutaneously with Ova-expressing E.G7 tumor cells and the progression 
of tumor volume monitored (Figure 2-5a). Tumor volumes were compared among treatments 
12 days post-tumor challenge, and time on study was evaluated at 30 days post-challenge. On 
day 12 post-challenge, tumor volumes in mice immunized with either the NP formulation or 
sOva alone were significantly lower compared to those of non-vaccinated control mice 
(Figure 2-5b). However, only the mice immunized with the NP formulation experienced a 
significant increase in survival at day 30 compared to the non-vaccinated controls (Figure 2-
5c). Together, these results demonstrate that a lower dose NP vaccine regimen was as 
effective as the high dose regimen with respect to the induction of an efficacious immune 
response.  
 
 
Figure 2-5. Polyanhydride nanoparticles induce CD8+ T cell memory with a low antigen 
dose.  
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Figure 2-5 Continued 
 
C57BL/6 female mice were immunized subcutaneously with formulations consisting 
of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride nanoparticles 
encapsulating 25 µg Ova (NP) (n=12); 100 µg soluble Ova alone (sOva) (n=11); or PBS 
control (n=12). Mice were challenged subcutaneously in the flank with E.G7 Ova expressing 
tumor cells 42 days post-immunization and (a) tumor volume of individual mice was tracked. 
(b) Tumor volume was compared when the first mouse was removed from study on day 12. 
Treatment groups were compared to PBS control using an ordinary one-way ANOVA with a 
Dunnett’s multiple comparison test. Significance is indicated as follows *p ≤ 0.05. Bar 
graphs indicate the group mean ± SEM. (c) Survival was evaluated 30 days post-challenge. 
Significance from PBS control was determined using a Log-rank (Mantel-Cox) test with a 
Bonferroni correction for multiple (2) comparisons. Significance from control is indicated in  
the legend as follows *p ≤ 0.025. Median survival of each group is also indicated 
parenthetically. 
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3.6 Polyanhydride NPs provided a more efficacious induction of CD8+ T cell memory 
upon vaccination compared to CpG ODN 
 The observed low inflammatory effects of polyanhydride NPs on DCs, as compared 
to the TLR agonist CpG ODN, lead to the hypothesis that the magnitude and/or 
consequences of differentially inflammatory adjuvants would alter the efficacy of the ensuing 
immune response. This hypothesis was tested by subcutaneously immunizing C57BL/6 mice 
with vaccine formulations containing a low dose of Ova (100 µg) as described above: NP, 
CpG ODN, NP + CpG ODN, or a naïve PBS only control. After implantation of the EG.7 
cells, tumor volumes were tracked (Figure 2-6a) and compared among groups at 14 days 
post-tumor challenge. As expected, the tumor volumes of mice receiving the overtly 
inflammatory regimen, CpG ODN + Ova, were not significantly different than those of the 
non-vaccinated control mice. However, tumor progression in mice immunized with either of 
the two NP formulations containing encapsulated Ova was significantly limited (Figure 2-
6b). At 30 days post-tumor challenge, time on study was significantly improved for mice 
immunized with either the NP + Ova formulation or the combination NP + CpG ODN + Ova 
formulation compared to unvaccinated control (Figure 2-6c). Vaccination with CpG ODN + 
Ova lead to no improvement in survival time compared to unvaccinated controls. These 
results suggest that polyanhydride NPs containing encapsulated antigen are able to initiate 
effective T cell memory on their own as well as when co-administered with the inflammatory 
TLR agonist CpG ODN. 
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Figure 2-6. Polyanhydride nanoparticles induce effective CD8+ T cell memory as 
compared to CpG ODN.  
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Figure 2-6 Continued 
 
C57BL/6 female mice (n=12) were immunized subcutaneously with formulations 
consisting of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride 
nanoparticles encapsulating 25 µg Ova (NP); 100 µg soluble Ova adjuvanted with 20 µg 
CpG ODN (CpG); a combination of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH 
polyanhydride nanoparticles encapsulating 25 µg Ova plus 20 µg CpG ODN (NP+CpG); or 
PBS control. Mice were challenged subcutaneously in the flank with E.G7 Ova expressing 
tumor cells 42 days post-immunization and (a) tumor volume of individual mice was tracked. 
(b) Tumor volume was compared when the first mouse was removed from study on day 14. 
Treatment groups were compared to PBS control using an ordinary one-way ANOVA with a 
Tukey posttest. Significance between treatments is indicated as follows *p ≤ 0.05. Bar graphs 
indicate the group mean ± SEM. (c) Survival was evaluated 30 days post-challenge. 
Significance from PBS control was determined using a Log-rank (Mantel-Cox) test with a 
Bonferroni correction for multiple (3) comparisons. Significance from naïve control mice is 
indicated in the legend as follows *p ≤ 0.016. Median survival of each group is also reported. 
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4. Discussion 
In this work, the ability of a polyanhydride nanoparticle-based vaccine to induce 
CD8+ T cell memory was investigated. Polyanhydride nanoparticles, encapsulating tumor 
antigen, enhanced the development of CD8+ T cell memory upon vaccination. This effect 
occurs without inducing the overt inflammatory responses commonly associated with innate 
immune stimulating microbial associated molecular patterns [7]. Direct in vivo comparison of 
the TLR agonist CpG ODN and the polyanhydride nanoparticle formulation illustrates the 
benefits of a low inflammatory vaccine adjuvant formulation on the resulting immune 
response. 
Previously, inclusion of a TLR agonist in the nanoparticle formulation negatively 
affected the ability 20:80 CPTEG:CPH polyanhydride NPs to inhibit tumor progression [12]. 
These observations suggest that the inclusion of a TLR agonist in the vaccine formulation 
inhibited or hindered the efficacy of the polyanhydride particle vaccine to induce either CD8+ 
T effector or memory cells. Inflammatory adjuvants, while effective at enhancing antibody 
production and expansion of terminally differentiated effector CD8+ T cells, often fail to 
induce optimal T cell memory populations among other adverse reactions [1,6,32,35,36]. 
Vaccination strategies that have been described to rapidly induce high numbers of CD8+ T 
cell memory, such as DC vaccination or antigen coated particle formulations, share an 
important quality [4,35,37]. The common feature of these strategies is that that they both 
induce CD8+ T cell memory more effectively when the antigen is delivered in the absence of 
overt inflammation.  
 One component of the overt inflammatory responses induced by pathogens or TLR-
based adjuvants is the production of microbicidal innate immune effector molecules such as 
NO [38,39]. Although NO is important for the innate immune system in overcoming acute 
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pathogenic infections [40], it has potential negative autocrine effects on APCs as well as 
paracrine effects on neighboring cells. When NO is produced by BMDCs, it inhibits the 
electron transport chain (i.e., oxidative phosphorylation), leading to a dependence on aerobic 
glycolysis for ATP production and cellular survival [9,33]. This sustained dependence on 
aerobic glycolysis, while not necessary for activation, has been described to provide the 
necessary energy demands for BMDC survival when stimulated via a TLR agonist [41]. 
Previous studies have also indicated that mitochondrial deficiencies are associated with 
suboptimal antigen processing and presentation [42]. In the present studies, the ability to the 
NP formulations to avoid adverse impacts on mitochondrial function in APCs and the 
resultant reliance on sustained glycolysis (Figure 2-4) may have contributed to a DC 
phenotype that more effectively promoted the induction of antigen-specific CD8+ T cell 
memory responses (Figures 2-1,2-5). Furthermore, production of high amounts of NO by 
DCs following TLR ligand stimulation can lead to decreased co-stimulatory capacity and 
survival [9,43]. This NO production by DCs and other innate immune cells has also been 
implicated in the direct inhibition of B cell (i.e., antibody production) and T cell function 
(i.e., effector and memory phenotypes) [29,31,44,45]. Pharmacological inhibition of NO 
production can prevent some of these deleterious effects on the adaptive immune response 
[29,43]. Compared to the robust stimulation of DCs by TLR ligands, the low inflammatory 
activation phenotype observed in DCs following polyanhydride particle stimulation likely 
contributes to the enhanced anti-tumor immune response demonstrated in our studies 
(Figures 2-3,2-4). 
Previous intervention strategies targeting the inflammatory response to enhance CD8+ 
T cell memory have focused on interfering with chemokine actions and chemokine effects on 
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lymphocytes [46–49]. Other strategies have inhibited the expansion of effector cells at 
strategic timepoints after immunization, such as dosing with the mTOR inhibitor rapamycin 
to interfere with the metabolic requirements of expanding effector cells to shift 
differentiation toward memory development [43,50,51]. Although these approaches have 
shown positive effects on DCs and memory CD8+ T cell induction following vaccination or 
after infection, the systemic effects of using these inhibitors may have unintended 
consequences. Reducing the magnitude of the inflammatory response associated with vaccine 
adjuvants may be able to provide many of these same benefits without the necessary post-
vaccination intervention with inhibitors such as rapamycin. Together, these studies along 
with the current observations, suggest that obtaining effective adaptive memory following 
vaccination can be induced using adjuvant formulations that provide optimal innate 
activation of APCs with “just right” adjuvant-induced inflammatory effects [52].  
Polyanhydride nanoparticle adjuvants have been shown to be endocytosed by APCs, 
provide innate immune activation, and induce co-stimulatory molecule upregulation. These 
activities of polyanhydride nanoparticles have contributed to the successful generation of 
long-lived protective antibody responses to various encapsulated protein antigens [12,14,53–
55]. In the present work, it was shown that a 20:80 CPTEG:CPH polyanhydride nanoparticle 
formulation induced antigen-specific CD8+ T cell memory capable of providing protection 
against a tumor challenge distant from the vaccination site at both high (Figure 2-1) and low 
dosages of antigen (Figure 2-5). This immune-enhancing effect was associated with the 
ability to activate DCs, particularly the CD8a+ subpopulation of DCs associated with cross-
priming CD8+ T cells (Figure 2-3). Such activation was accomplished in the absence of 
deleterious vaccination site inflammation, which can lead to dysfunctional CD8+ T cell 
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trafficking and effector functions. Further, it was demonstrated that the delivery of empty 
nanoparticles with soluble antigen did not provide the same benefits as particulate 
formulations including encapsulated antigen. This finding suggests that there is a critical role 
for antigen encapsulation in the capability of polyanhydride NP formulations to induce CD8+ 
T cell memory (Figure 2-2). The benefits of antigen encapsulation with a single dose regimen 
that provide comparable results of prime-boost formulations was also described (Figure 2-2). 
Direct in vivo comparison of polyanhydride nanoparticles with the TLR agonist CpG ODN, 
illustrates the effectiveness of the low inflammatory nature at work to provide significantly 
greater survival and decreased tumor burden while the CD8+ T cell memory induced by CpG 
ODN vaccination failed to do so (Figure 2-6). Related to its phlogistic potential, the addition 
of CpG ODN to vaccine formulations has been shown to limit the effectiveness of the 
polyanhydride nanovaccine [4,17,56]. This suggests that the nature of the innate 
inflammatory phenotype induced by a vaccine plays a key role in the outcome of CD8+ T cell 
response. It is also of note that in this study the addition of CpG ODN to the polyanhydride 
nanoparticle formulation did not have the same decreased survival. This observation suggests 
that the encapsulation of antigen and persistence of the polyanhydride particles allows the 
host to overcome the apparent negative impact of the acute inflammatory response induced 
by CpG ODN at the time of immunization (Figure 2-6). 
In conclusion, these results suggest that the beneficial effects of polyanhydride 
nanoparticles arise, in part, from their ability to activate DCs without excessive induction of 
inflammatory cytokines, chemokines, and effector molecules (e.g., NO) associated with a 
pathogenic infection or TLR ligand administration. The use of adjuvants that closely mimic 
the immunological response to infection has been successful in generating protective 
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antibody mediated immunity, but many of these adjuvants are associated with poor CD8+ T 
cell responses. By virtue of their low inflammatory activation properties (i.e., selectively 
pathogen mimicking), polyanhydride nanoparticles are emerging as a vaccine option to more 
effectively generate CD8+ T cell memory without the induction of deleterious innate 
inflammatory effects. 
 
5. Supplemental Data 
 
Figure 2-7. 20:80 CPTEG:CPH polyanhydride nanoparticles provide highest degree of 
tumor protection. C57BL/6 female mice (n=12) were immunized subcutaneously with 
formulations consisting of 1.75 mg soluble Ova plus 5 mg of either 20:80 CPTEG:CPH, 
50:50 CPTEG:CPH, or 20:80 CPH:SA encapsulating 250 µg Ova, or PBS (control). Mice 
were challenged subcutaneously in the flank with E.G7 Ova expressing tumor cells 47 days 
post-immunization and tumor volume of individual mice was tracked. Graph indicates the 
group mean ± SEM. 
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Figure 2-8. Polyanhydride nanoparticles provide no protection against the parent EL4 
non-Ova expressing tumor. C57BL/6 female mice (n=4) were immunized subcutaneously 
with formulations consisting of 1.75 mg soluble Ova plus 5mg of 20:80 CPTEG:CPH 
polyanhydride nanoparticles encapsulating 250 µg Ova (NP); 2 mg soluble Ova (sOva); or 
PBS (control). Mice were challenged subcutaneously in the flank with EL4 tumor cells 40 
days post-immunization and (a) tumor volume of individual mice was tracked. (b) Tumor 
volume was compared when the first mouse was removed from study on day 12. Treatment 
groups were compared to PBS control using an ordinary one-way ANOVA with a Dunnett’s 
multiple comparison test. Significance is indicated as follows *=p<0.05. Bar graphs indicate 
the group mean ± SEM. (c) Survival was evaluated 30 days post-challenge. Significance 
from PBS control was determined using a Log-rank (Mantel-Cox) test with a Bonferroni 
correction for multiple (2) comparisons. Significance from control is indicated in the legend 
as follows *p ≤ 0.025. Median survival of each group is also reported parenthetically. 
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Figure 2-9. BMDCs stimulated with polyanhydride nanoparticles secrete lower levels of 
proinflammatory cytokine and chemokines than those stimulated with CpG ODN. 
BMDCs generated from naïve BALB/c mice were stimulated for 48 hours with (a) CpG 
Nanoparticles
CpG
Control
a
b
c
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ODN plus Ova; (b) 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating Ova (5% 
w/w); (c) or unstimulated control as described in Materials and Methods section. Cytokine 
concentration in the supernatants were quantified using a 42-plex assay. Numbers denoting 
concentric circles represent the cytokine concentration (pg/mL). Each cytokine measured in 
the supernatant is denoted by a solid red line. 
 
 
Figure 2-10. Splenic DCs stimulated with polyanhydride nanoparticles secrete lower 
levels of proinflammatory cytokine and chemokines than those stimulated with CpG 
ODN.  
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Figure 2-10 Continued 
  Splenic DCs isolated from naïve BALB/c mice were stimulated for 48 hours with (a) 
CpG ODN plus Ova; (b) 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating Ova 
(5% w/w); (c) or unstimulated control as described in Materials and Methods section. 
Cytokine concentration in the supernatants were quantified using a 42-plex assay. Numbers 
denoting concentric circles represent the cytokine concentration (pg/mL). Each cytokine 
measured in the supernatant is denoted by a solid red line. 
 
Figure 2-11. Polyanhydride nanoparticle stimulation of BMDCs does not result in the 
induction of mitochondrial superoxide. 20:80 CPTEG:CPH polyanhydride nanoparticles 
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encapsulating Ova (5% w/w) (NP), CpG ODN (CpG) Ova, or unstimulated control (Cont.) 
were used to stimulate BMDCs as described in Materials and Methods section were assayed 
for mitochondrial superoxide production via MitoSOX staining and resulting MFI collected 
via flow cytometry. Significance was determined via one-way ANOVA with a Sidak’s  
multiple comparison test. Significance is indicated as *=p<0.05. All bars and symbols 
represent the treatment average ± SEM. Data include two stimulation replicates 
 
 
Figure 2-12. Polyanhydride nanoparticles do not upregulate BMDC glycolytic 
metabolism in response to stimulation. BMDCs generated from BALB/c mice were 
stimulated for 18 h with 20:80 CPTEG:CPH polyanhydride nanoparticles (NP), CpG ODN 
(CpG), or non-stimulated control (Cont.). Stimulated BMDCs were seeded into 24 well 
seahorse plates coated with Cell-Tak at a density of 2.5 x 105 cells per well and a 
mitochondrial stress test (MST) was conducted. (a) Kinetic results of a portion of the MST 
extracellular acidification rate (ECAR) are shown along with (b) basal ECAR. Significance 
between treatments was determined via one-way ANOVA with a Tukey posttest. P value is 
indicated as *p ≤ 0.05. All bar graphs and symbols represent the treatment average ± SEM. 
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Figure 2-13. Vaccinated mice generated anti-Ova IgG antibody titers. C57BL/6 female 
mice (from Fig. 6) (n=12) were immunized subcutaneously with formulations consisting of 
75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride nanoparticles 
encapsulating 25 µg Ova (NP), 100 µg soluble Ova adjuvanted with 20 µg CpG ODN (CpG), 
a combination of 75 µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH polyanhydride 
nanoparticles encapsulating 25 µg Ova adjuvanted with 20 µg CpG ODN (NP+CpG), or PBS 
control. Serum samples were collected 5 weeks post-immunization. Total IgG antibody titers 
were measure using indirect ELISA. Limit of detection indicated by the dashed line. 
Significance between each treatment and control was determined via one-way ANOVA with 
a Dunnett’s posttest. P value is indicated as *p ≤ 0.05. All bar graphs and symbols represent 
the treatment average ± SEM. 
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Abstract 
Background: One of the most concerning public health issues, related to vaccination 
and disease prevention, is the inability to induce durable immune responses following a 
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single-dose immunization. In this regard, the nature of the inflammatory environment 
induced by vaccine adjuvants can negatively impact the resulting immune response. To 
address these concerns, new strategies to vaccine design are needed in order to improve the 
outcomes of immune responses, particularly in immunologically disadvantaged populations. 
Methods: Comparisons of the scope of innate immune activation induced by TLR agonists 
versus cyclic dinucleotides (CDNs) was performed. Their effects on the activation 
characteristics (e.g., metabolism, cytokine secretion) of bone marrow derived dendritic cells 
(BMDCs) were studied. In addition, the differential effects on in vivo induction of antibody 
responses were measured. 
Results: As compared to TLR ligands, the stimulation of BMDCs with CDNs induced 
distinctly different metabolic outcomes. Marked differences were observed in the production 
of nitric oxide (NO) and the cytokine BAFF.  These distinct differences were correlated with 
improved (i.e., more rapid and persistent) vaccine antibody responses in both aged and young 
mice. 
Conclusions:  Our results illustrate that the innate immune pathway targeted by adjuvants can 
critically impact the outcome of the immune response post-vaccination.  Specifically, CDN 
stimulation of APCs induced an activation phenotype that was characterized by decreased 
innate effector molecule production (e.g., NO) and increased BAFF. This was attributed to 
the induction of an innate inflammatory environment that enabled the host to make the most 
of the existing B lymphocyte potential. The use of adjuvants that differentially engage 
mechanisms of innate immune activation would be particularly advantageous for the 
generation of robust, single dose vaccines. The results of this study demonstrated that CDNs 
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induced differential innate activation and enhanced vaccine induced antibody responses in 
both young and aged mice.   
1. Introduction 
As a result of their relatively low immunogenicity, recombinant subunit-based 
vaccine formulations generally require the addition of adjuvants to induce protective 
immunological responses [1,2]. One of the often-selected families of adjuvants are Toll-like 
receptor (TLR) ligands [3]. These are chosen for their ability to provide activation (i.e., 
induce inflammation) of the innate and adaptive immune system through ligation of pattern 
recognition receptors (PRRs) to effectively mimic the presence of an active infection. While 
effective at activating innate immune responses, TLR engagement leads to the production of 
reactive nitrogen and reactive oxygen species by innate immune cells [4].  
While production of nitric oxide (NO) and mitochondrial reactive oxygen species 
(mROS) are often central in the clearance of pathogenic infections prior to development of 
adaptive immunity, each are known to have deleterious effects on the magnitude of activation 
as well as the phenotype and survival of innate and adaptive immune cells [5–10]. For 
example, mice infected with lymphocytic choriomeningitis virus (LCMV) which develop 
severe lymphopenia have a poor adaptive immune response (e.g., no neutralizing antibody) 
that has been attributed to the large amounts of NO produced by inflammatory monocytes in 
the lymph nodes [11]. The elevated levels of NO leads to B cell death, decreased production 
of BAFF (i.e., cytokine promoting B cell survival), and subsequent loss of antibody 
production [12–15]. NOS2 derived NO from innate immune cells has also been described to 
interfere with lymphatic function and flow that can impair the adaptive immune response 
[16]. ROS have also been described to influence the phenotypic differentiation of B cells to 
plasma cells or immunoglobulin class switching in germinal center B cells. Varying levels of 
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ROS will react with and inhibit the ability of heme to regulate critical B cell transcription 
factors determining B cell fate [17]. While beneficial for acute innate immune responses, 
excessive levels of NO and/or ROS may have a negative impact on the adaptive immune 
response. In this regard, proper “management” of the inflammatory response induced by 
vaccine adjuvants needs to be carefully considered especially for older adults [18]. 
Those with immunological deficiencies, such as older adults developing an age-
related narrowing of the naïve lymphocyte repertoire leading to less than adequate antibody 
responses, must make the most of the limited number of naïve cells remaining [19–21]. This 
will require the identification of more optimal activation pathways for adjuvants to target or 
avoid targeting, and will be critical in order to achieve the broadest protective response to 
recombinant subunit vaccines. Besides TLRs, another, independent receptor family 
interacting with microbial associated molecular patterns (MAMPs) or damage associated 
molecular patterns (DAMPs) are the cytosolic nucleic acid sensors, such as Stimulator of 
Interferon Genes (STING) [22–25]. Herein, the ability of STING targeting cyclic 
dinucleotides (CDNs), specifically a synthetic analog of cyclic di-GMP (cdG), to provide 
effective innate immune activation and adjuvanticity was evaluated. While STING 
stimulation induces inflammation, we show that CDNs did not induce deleterious amounts of 
innate effector molecules (e.g., NO and ROS) that are associated with TLR agonist-based 
adjuvants [26,27]. We also illustrate that the activation of the STING pathway results in a 
distinct metabolic profile of DCs which is indicative of a unique activaton phenotype as 
compared to TLR agonist. The results of this study furthers our understanding of adjuvant 
properties that contribute to the induction of durable protective immunity while avoiding the 
adverse reactions associated with adjuvants such as Alum or TLR agonists. Specifically, 
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these studies demonstrate that the use of CDNs induce a more favorable early innate immune 
activation phenotype and associated inflammatory environment which is linked to a rapid and 
greater magnitude of the vaccine-induced antibody responses in both aged and young mice. 
 
2.0 Materials and Methods 
2.1 Animals 
Female BALB/c or C57BL/6 mice of six to eight weeks of age were obtained from 
Charles River (Wilmington, MA) for young mouse vaccination studies as well as in vitro 
APC studies. Aged female BALB/c mice of ≥ 20 months of age were obtained from Jackson 
Laboratory (Bar Harbor, ME). All studies involving the use of animals was carried out in 
accordance with current institutional guidelines for the care and use of animals. 
 
2.2 Vaccination Studies 
Young (6-8 weeks) and aged (18+ months) female BALB/c mice were immunized 
subcutaneously at the nape of the neck with formulations consisting of 50 µg ovalbumin 
(Ova), and 20 µg of the indicated TLR ligand or CDN (dithio-RP,RP-cyclic di-guanosine 
monophosphate) (Aduro Biotech, Berkley, CA) adjuvant, or where indicated Ova alone. 
Where applicable N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamine, dihydrochloride 
(1400W) (Cayman Chemical, Ann Arbor, MI) was administered intraperitoneally at 5 mg/kg 
body weight, every eight hours for seven days following vaccination. Female C56BL/6 mice 
(6-8 weeks of age) were immunized with 20 µg of recombinant protective antigen (PA) from 
B. anthracis (BEI, NR-3780) along with 20 µg of CDNs, or with 50 µL of the commercial 
BioThrax Anthrax Vaccine Adsorbed (Emergent Biosolutions, Rockville, MD) 
subcutaneously at the base of the neck. 
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2.3 Extracellular Flux Analysis 
For mitochondrial stress tests (MST), BMDCs were stimulated overnight with 0.5 
µg/mL CDNs, 1 µg/mL LPS or MPLA, 5 µg/mL imiquimod, CpG ODN, or no stimulation 
control in 5 mL polypropylene tubes (to avoid cell adherence). Treated BMDCs were seeded 
into 24 well seahorse plates coated with Cell-Tak (Corning, Corning NY) at a density of 2.5 
x 105 cells per well. Mitochondrial stress test was carried out according to manufacturer’s 
MST protocol (Agilent, Santa Clara, CA). Concentrations of 1 µM oligomycin, 2 µM FCCP, 
and 0.5 µM rotenone and antimycin were used (Agilent, Santa Clara, CA). Kinetic 
stimulation assays were conducted with non-stimulated BMDCs seeded at 2.5 x 105 cells per 
well in 24 well seahorse plates coated with Cell-Tak (Corning, Corning NY). Stimulants 
were injected at the concentrations outlined in the APC stimulation section, after the third 
baseline measurement interval. Metabolic phenotyping was conducted on a Seahorse XFe24 
(Agilent, Santa Clara, CA).  
 
2.4 Bone marrow dendritic cell and macrophage generation 
Bone marrow was collected from femurs and tibias of BALB/c mice. Cells (4 x 106 
cells per 100 mm plate) were washed and plated in 10 mL of complete RPMI 1640 medium 
(100 U/mL penicillin and 100 µg/mL streptomycin, 2 mM glutamine, and 10 % FBS) was 
supplemented with 10 ng/mL of GM-CSF (Peprotech, Rocky Hill, NJ). On day three of 
culture, 10 mL of GM-CSF containing complete medium was added.  On days six and eight 
of culture, 10 mL of culture medium was exchanged for 10 mL of fresh GM-CSF containing 
complete medium. On day 10 of culture, DCs were harvested by gently rinsing and collecting 
non-adherent cells. The same protocol was used to generate BMMs but substituting M-CSF 
in place of GM-CSF.  
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2.5 In vitro APC stimulation 
BMDCs or BMMs were plated at 5 x 105 cells/well in a 96-well round bottom tissue 
culture plate in 200 µL of the previously described complete RPMI 1640 medium. Stimulants 
used included 5 µg/mL CpG ODN 1668, 5 µg/mL imiquimod, 1 µg/mL LPS, 1 µg/mL 
MPLA, 0.5 µg/mL cyclic di-GMP (cdg) CDN, or non-stimulated control wells (i.e., medium 
alone). Stimulations were carried out for 48 hours and supernatants and cells were harvested 
for cytokine analysis and cell surface maker expression by flow cytometry. In in vitro 
experiments, the NOS2 inhibitor 1400W was used at a concentration of 50 µM. 
 
2.6 Flow Cytometry 
Following stimulation APCs were analyzed for costimulatory marker expression 
using flow cytometry. 5 x 105 DCs were aspirated from a 96 well plate and transferred to 
polystyrene tubes. Prior to labeling with specific monoclonal antibodies, Fc receptors on DCs 
were blocked to prevent non-specific antibody binding by incubating the cells with 100 
µg/mL of rat IgG (Sigma Aldrich, St. Louis, MO) and 10 µg/mL of anti-CD16/32 
(eBioscience). Subsequently, DCs were stained with fluorescently conjugated antibodies for 
CD80 (Biolegend, PerCP-Cy5.5, clone 16-10A1), CD86 (eBioscience, FITC, clone GL1), 
CD11c (Biolegend, APC-Cy7, clone N418), MHCII (eBioscience, AF700, clone 
M5/114.15.2) diluted in FACS buffer. Mitochondrial superoxide production was evaluated 
using live cells stained with MitoSOX Red according to manufacturer’s specifications 
(ThermoFisher Scientific). Samples were fixed using BD stabilizing fixative where 
applicable (BD Bioscience, Franklin Lakes, NJ). Data was collected on a FACSCanto II (BD 
Bioscience, Franklin Lakes, NJ), and analyzed using FlowJo (Flowjo LLC).  
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2.7 Nitric oxide quantification 
Nitric oxide (NO) was quantified in BMDC supernatants via Griess assay. A sodium 
nitrite standard curve was created using two-fold serial dilutions with concentrations ranging 
from 100 µM to 0 µM. 100 µL of standard or supernatant was added to 100 µL of Griess 
reagent (Cat. No. 03553, Sigma-Aldrich) in a 96 well microtiter plate. Samples were allowed 
to react for 15 minutes at room temperature and the optical density at 540 nm was recorded 
using a SpectraMAX 190 (Molecular Devices, Sunnyvale, CA). Concentrations of nitrite 
were calculated using a linear regression method. 
 
2.8 BAFF quantification 
 Quantification of serum BAFF, collected at seven days post-vaccination, and DC 
supernatant BAFF was performed via ELISA.  A murine BAFF/BLyS/TNFSF13B 
Quantikine ELISA kit (R&D Systems, Cat. No. MBLYS0, Minneapolis, MN) was used 
according to manufacturer’s instructions and the optical density at 540 nm was recorded 
using the SpectraMAX 190. Concentrations of serum and supernatant BAFF were calculated 
using a linear regression method. 
 
2.9 Serum antibody detection 
Vaccinated mice were bled via saphenous vein at the indicated timepoints post-
vaccination. Anti-Ova serum antibody titers were measured via indirect ELISA. Costar 3590 
96-well EIA/RIA high binding plates (Corning, Corning NY) were coated with 100 µL of 
Ova (5 µg/mL PBS) or PA (0.5 µg/mL PBS) and incubated overnight at 4C. Plates were 
blocked using 2 % (w/v) Difco gelatin in PBS (0.05 M, PH 7.2) containing 0.05% Tween-20 
(PBS-T) for two hours at room temperature. After three washes using PBS-T, serum samples 
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were titrated across the plate using two-fold serial dilutions, starting at 1:200, in PBS-T and 
1% (v/v) normal goat serum.  Samples were incubated overnight at 4C. After three washes in 
PBS-T, an alkaline phosphatase conjugated goat anti-mouse IgG (H+L) secondary detection 
antibody (Cat# 115-005-003, Jackson ImmunoResearch) was diluted 1:1000, added to the 
wells and allowed to incubate at room temperature for two hours. Plates were washed three 
times with PBS-T and alkaline phosphatase substrate was added at 1 mg/mL in buffer 
containing 50 mM sodium carbonate, 2 mM magnesium chloride, and sodium bicarbonate 
added to achieve a pH of 9.3. Plates were allowed to develop for 30 minutes and analyzed 
using the SpectraMAX 190 at a wavelength of 405 nm. For isotype specific a similar ELISA 
protocol was used, but serum samples were diluted 1:200 and IgG1 (Cat# 115-055-205, 
Jackson ImmunoResearch and IgG2a (Cat# 115-055-206, Jackson ImmunoResearch) specific 
secondary antibodies were used. 
 
3. Results 
3.1 CDNs result in higher antibody titers when compared to TLR agonists 
 Studies incorporating the use of CDNs in recombinant subunit vaccine studies have 
illustrated the ability of CDNs to enhance the induction of durable, high titer antibody after 
vaccination [28]. Herein, the antibody titers induced in mice that received TLR agonist or 
CDNs were compared (Figure 3-1). Mice were vaccinated with 50 µg of Ova alone, or 
adjuvanted with either 20 µg of monophosphoryl lipid A (MPLA) or Imiquimod as 
representative TLR ligands, or 20 µg of CDN. Antibody titers were measured at 14- and 28-
days post-vaccination. Animals that had received vaccination with CDNs as the adjuvant had 
higher serum anti-Ova IgG titers compared to mice that had been vaccinated using TLR 
agonists as the adjuvant at both 14 and 28 days after vaccination (Figure 3-1a-b). CDNs were 
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also compared to a vaccine containing the commonly used adjuvant alum. To demonstrate 
that the difference in the magnitude of the immune response induced with CDNs was not 
specific to Ova, it was also shown that higher serum antibody titers were achieved after 
vaccination with the protective antigen (PA) of B. anthracis admixed with CDNs as 
compared to the commercially available alum-based vaccine, Biothrax (Supplemental Figure 
3-7). 
 
Figure 3-1. Assessment of the murine serum antibody response to ovalbumin (Ova) when 
adjuvanted with cyclic dinucleotides (CDNs) or TLR-ligands. Young (6-8-week-old) female 
BALB/c mice were immunized subcutaneously with formulations consisting of 50 µg Ova 
alone or with the addition of 20 µg of the indicated TLR ligand (Imiquimod (Imiq) or 
monophosphoryl lipid A (MPLA)) or CDN as an adjuvant (n=8). Serum antibody titer to Ova 
was quantified via ELISA at (a) 2-weeks and (b) 4-weeks post-immunization. Titer values 
were Log2 transformed and compared for statistical significance via an ordinary one-way 
ANOVA with a Dunnett’s multiple comparison test with each group being compared back to 
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CDN. P value is indicated as follows (*=p<0.05). Individual animals are shown with bars 
indicating mean ± SEM. 
 
3.2 CDN stimulation of BMDCs results in early dual metabolic burst and sustained 
mitochondrial respiration 
Stimulation and activation of BMDCs has been described to cause distinct acute, and 
long term, metabolic alterations in response to encounter and activation upon exposure to 
TLR agonists [29–31]. Immediately upon stimulation with TLR ligands, a hallmark 
glycolytic burst is observed. Stimulation with CDNs also results in a comparable uptick in 
glycolytic rate upon activation, albeit a somewhat slower response (Figure 3-2a-b). While 
TLR ligand stimulation results in no immediate increase in mitochondrial respiration after 
stimulation, CDN stimulation results in an upregulation of oxygen consumption rate in 
addition to the observed glycolytic burst (Figure 3-2c-d).  
Mitochondrial function was analyzed after an 18-h stimulation with CDNs and TLR 
agonists.  The TLR ligand results are consistent with previous observations that BMDCs are 
driven to a persistent state of aerobic glycolysis and inhibited mitochondrial function [29,32]. 
CDN mediated activation results in a sustained basal oxygen consumption rate, ATP 
production, decreased proton leak, and maintenance of spare capacity (Figure 3-2e-f) while 
TLR stimulation results in depressed functionality of mitochondria (Figure 3-2e-f). Similar 
decreases in mitochondrial respiration are also observed in the monocyte like J774 cell line 
after 18 h of stimulation with TLR agonists, but not with CDNs (Supplemental Figure 3-8). 
The relationship between metabolism and phenotypic outcome of cells is described to be 
closely linked [33–35]. These results illustrate a differential metabolic phenotype arose, as 
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well as a corresponding distinct activation phenotype, depending on the PRR activation 
pathway engaged by these adjuvants. 
Figure 3-2. Acute metabolic responses and long-term mitochondrial function. Acute and 
chronic metabolic responses of bone marrow derived dendritic cells (BMDCs) stimulated 
with cyclic dinucleotides (CDNs) or TLR ligands. For acute assays non-stimulated BMDCs 
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were seeded at 2.5 x 105 cells per well in a Seahorse plate coated with Cell-Tak. Extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR) were measured as indicators 
of glycolysis and mitochondrial respiration respectively. (a-d) After three baseline readings 
either CDNs, Imiquimod, MPLA, or medium control were injected into each well at the 
indicated time point (n=3). (b) ECAR % and (d) OCR % change relative to baseline readings 
at 100 minutes. For longer term mitochondrial stress test (MST), (e) BMDCs were stimulated 
for 18 h with CDNs, Imiquimod (Imiq), lipopolysaccharide (LPS), CpG, or non-stimulated 
control in 5 mL polypropylene tubes. Stimulated BMDCs were seeded into seahorse plates 
coated with Cell-Tak at a density of 2.5 x 105 cells per well and oxygen consumption rate 
(OCR) was measured. (f) Basal respiration, ATP production, maximal respiratory capacity, 
and spare capacity are calculated from the MST. Significance (p<0.05) was determined via 
one-way ANOVA with a Dunnett’s (b) or Sidak’s (d-f) multiple comparison test. 
Significance is indicated as compared to control with (*) and as compared to CDN with (#), 
respectively. All bars and symbols represent the group average ± SEM. Data shown is a 
single experimental replicate that is representative of at least one additional experimental 
repeat. 
 
3.3 CDN stimulation results in decreased innate immune effector molecule production 
and increased BAFF 
 The sustained aerobic glycolysis observed in murine BMDCs after TLR stimulation is 
the direct result of the production of high concentration of nitric oxide (NO) leading to 
nitrosylation of electron transport chain molecules [31,36]. This results in mitochondrial 
deficiency and dependence on glycolysis for survival and the metabolic demands of 
activation [32]. After observing the acute characteristic metabolic effects of activation, yet 
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maintenance of mitochondrial function of CDN stimulated BMDCs at later time points, it 
was hypothesized that there would be low to no production of the innate effector molecule 
NO. After 48 hours, CDN stimulation results in control levels of NO accumulation in the 
supernatant, while TLR ligands induce a dramatic upregulation of NO concentrations (Figure 
3-3a). Bone marrow macrophages (BMM) as well as monocyte like J774 cells also show 
similar patterns of low NO production after stimulation with CDN (Supplemental Figure 3-
9). As glycolytic reprogramming upon activation in macrophages has been linked to 
production of reactive oxygen species, we also assayed stimulated BMDCs for mitochondrial 
superoxide (mROS) [37]. Similar patterns are again observed in the production of mROS 
after stimulation. CDNs result in control levels of mROS generation while TLR ligand 
stimulation overall resulted in an increase (Supplemental Figure 3-10).  
BAFF is a critical cytokine in promoting B cell and plasma cell survival, as well as 
maintenance of germinal centers and B cell follicles [12,13,15,38]. As NO is a known 
inhibitor of the production of BAFF expression, it was hypothesized that that the extremely 
low production of NO from CDN stimulated BMDC, would allow for the generation of 
higher levels of BAFF expression. Supernatant concentrations of BAFF were measured after 
48 hours of stimulation with CDNs or TLR ligand via ELISA. As hypothesized CDN 
stimulation lead to higher concentrations of supernatant BAFF (Figure 3-3b). 
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Figure 3-3. Comparison of nitric oxide (NO) and BAFF produced by bone marrow 
derived dendritic cells (BMDCs) stimulated with cyclic dinucleotides (CDNs) or TLR-
ligands. Supernatants were collected from BMDCs after 48 hrs. of stimulation with CDNs, 
CpG, Imiquimod (Imiq), lipopolysaccharide (LPS), monophosphoryl lipid A (MPLA), or 
Non-stimulated control as described in Materials and Methods section 3.6. The supernatants 
were assayed for (a) NO production was measured via Griess assay detection of supernatant 
nitrite, and (b) supernatant BAFF concentrations were measured via ELISA. All histograms 
represent the group average ± SEM. Significance was determined via one-way ANOVA with 
a Sidak’s multiple comparison test. Significance is indicated as compared to control with (*) 
and as compared to CDN with (#), respectively. P value is indicated as follows (* or 
#=p<0.05). Data shown is a single experimental stimulation with (a) n=4 Griess replicates, or 
(b) n=2 BAFF ELISA replicates. 
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3.4 In vitro NOS2 inhibition improves TLR induced BAFF production and 
costimulatory expression, but not CDNs.  
It has been illustrated via the use of NOS2 knockout mice and in vitro NOS2 
inhibitors that NO suppresses TLR agonist-mediated costimulatory molecule upregulation on 
BMDCs [14,36]. Therefore, BMDCs were stimulated with CDNs or TLR ligands in the 
presence or absence of the NOS2 inhibitor 1400W. After 48 hours, supernatants were 
harvested and assayed for NO production. Results showed that the NOS2 inhibitor was 
effective at significantly decreasing NO concentrations in TLR agonist stimulated cells 
(Figure 3-4a). BMDC culture supernatants were also analyzed for BAFF production after 
stimulation with or without 1400W. Increases in BAFF production in TLR stimulation 
groups that have NOS2 activity inhibited are observed, but not in CDN stimulated cells 
(Figure 3-4b). Like BAFF production, upregulation of the costimulatory molecules CD86 
and CD80 after stimulation with CDNs is unaffected by inhibition of NOS2 while TLR 
ligand stimulated groups have enhanced upregulation of these molecules (Figure 3-4c-d). 
This suggests that CDN stimulation of the STING pathway in BMDCs leads to an enhanced 
upregulation of the costimulatory molecules and increased BAFF production, compared to 
TLR ligands, by avoiding production of the innate effector molecule NO.  
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Figure 3-4. Effect of NOS2 inhibition on the costimulatory expression and BAFF secretion 
of innate immune cells. BMDCs were stimulated for 48 hrs. with CDNs, CpG, Imiquimod, 
LPS, MPLA, or non-stimulated control as described in Materials and Methods section 3.6. 
Each stimulant was given/used alone (-) or with the NOS2 inhibitor 1400w (+) and 
supernatants collected and were assayed for (a) NO production via Griess assay detection of 
supernatant nitrite, (b) supernatant BAFF concentrations via ELISA, and costimulatory 
expression of (c) CD86 and (d) CD80 expression via flow cytometry. All histograms 
represent the group average ± SEM. Statistical significance was determined between each 
stimulant alone (-), and the stimulant with 1400W present (+) via multiple Unpaired t-tests 
CD
N(
-)
CD
N(
+)
LP
S(-
)
LP
S(+
)
Im
iq(
-)
Im
iq(
+)
Cp
G(
-)
Cp
G(
+)
MP
LA
(-)
MP
LA
(+)
Co
nt.
(-)
Co
nt.
(+)
0
500
1000
1500
BA
FF
 p
g/
m
L
✱
✱
CD
N(
-)
CD
N(
+)
LP
S(-
)
LP
S(+
)
Im
iq(
-)
Im
iq(
+)
Cp
G(
-)
Cp
G(
+)
MP
LA
(-)
MP
LA
(+)
Co
nt.
(-)
Co
nt.
(+)
0
10
20
30
40
50
60
70
µM
 N
itr
ite
ns ns
✱
✱
✱
✱
CD
N(
-)
CD
N(
+)
LP
S(-
)
LP
S(+
)
Im
iq(
-)
Im
iq(
+)
Cp
G(
-)
Cp
G(
+)
MP
LA
(-)
MP
LA
(+)
Co
nt.
(-)
Co
nt.
(+)
0
10000
20000
30000
CD
86
 M
FI
✱ ✱
CD
N(
-)
CD
N(
+)
LP
S(-
)
LP
S(+
)
Im
iq(
-)
Im
iq(
+)
Cp
G(
-)
Cp
G(
+)
MP
LA
(-)
MP
LA
(+)
Co
nt.
(-)
Co
nt.
(+)
0
2000
4000
6000
8000
10000
CD
80
 M
FI
✱ ✱
✱
a b
c d
118 
(one-tailed). P value is indicated as follows (*=p<0.05). Data shown includes three 
independent experiments. 
 
3.5 Short term In vivo inhibition of NO results in improved antibody titers 
 As improved costimulatory expression and BAFF secretion was observed in vitro 
with TLR agonist/1400W treated BMDCs, it was hypothesized that inhibiting in vivo NOS2 
activity during the acute inflammatory period after vaccination would result in increased 
antibody titers.  This was tested by vaccinating mice with Ova alone, Ova adjuvanted with 
MPLA, or Ova adjuvanted with CDNs. In addition, mice also received an injection of 1400W 
or a sham injection three times daily for 7 days. Serum antibody titers were measured at 2 
weeks, 6 weeks, and 32 weeks post-vaccination. Anti-Ova IgG titers at 2 weeks post-
vaccination reveal improved titers in MPLA mice receiving inhibitor as compared to MPLA 
only mice, but treatment with the NOS2 inhibitor did not improve the antibody response in 
the CDN treated mice (Figure 3-5a). 6 weeks after vaccination the inhibitor did not result in a 
statistically significant increase in titer when inhibitor was added relative to adjuvant alone 
(Figure 3-5b). At 32 weeks post-vaccination time point, beneficial effects were observed for 
mice treated with MPLA and the NOS2 inhibitor.  Interestingly, the CDN treated mice 
receiving the NOS2 inhibitor also exhibited an increase in titer as compared to those 
receiving CDNs alone (Figure 3-5c). No notable difference in IgG1 vs IgG2 isotypes were 
observed (Supplemental Figure 3-11). 
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Figure 3-5. Assessment of the murine serum antibody response to ovalbumin (Ova) 
when adjuvanted with cyclic dinucleotides (CDNs) or TLR-ligand in the presence or 
absence of a NOS2 inhibitor. Young (6-8 weeks) female BALB/c mice were immunized 
subcutaneously with formulations consisting of 50 µg Ova alone (sOva) or with 20 µg of 
MPLA or CDN as an adjuvant. Mice were treated with MPLA or CDNs alone (-) or were 
treated intraperitoneally with the NOS2 inhibitor 1400W (+) for 7 days post-immunization 
(n=6). Serum antibody titer was quantified via ELISA at (a) 2-weeks and (b) 6-weeks (c) 32-
weeks post-immunization. Titer values were Log2 transformed and each treatment group was 
compared to itself with and without 1400W. Individual values for each mouse in a given 
treatment group are depicted by the symbols and the group average ± SEM is also indicated. 
Statistical significance was determined via multiple Unpaired t-tests (one-tailed). P value is 
indicated as follows (*=p<0.05), ns = not significant. 
 
3.6 CDN vaccination results in increased BAFF and antibody titer in aged recipients 
 NO production following in vitro stimulation, or vaccination with a TLR ligand as the 
adjuvant has deleterious effects on the generation of critical cytokines (e.g. BAFF), and of 
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antibody titers (Figure 3-5) [10,11]. It was hypothesized that immunologically compromised 
populations that often respond poorly to vaccination, such as older adults, would benefit (i.e., 
higher Ag-specific titers) from a vaccine formulation containing CDNs as opposed to a TLR 
ligand. Aged mice (≥ 20 months old) were vaccinated with Ova adjuvanted with either CDNs 
or the TLR7 ligand, imiquimod. Serum anti-Ova antibody titers were measured at 28- and 
75-days post-vaccination. Mice receiving the CDN adjuvanted vaccine regimen had higher 
antibody titers as compared to mice receiving Imiquimod at both time points (Figure 3-6a). 
We hypothesized that mice receiving the CDN formulation would have increased BAFF 
concentration after vaccination as compared to Imiquimod as CDNs do not result in NO 
production. Serum concentrations of BAFF were measured 7 days post-vaccination, and aged 
mice receiving CDNs had significantly increased serum BAFF concentrations as compared to 
those treated with imiquimod (Figure 3-6b).  
 
 
Figure 3-6. Assessment of serum BAFF and antigen-specific antibody responses in aged 
mice following vaccination. Aged (20+ months) female BALB/c mice were immunized 
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subcutaneously with formulations consisting of 50 µg Ova plus 20 µg of imiquimod (Imiq) 
or cyclic dinucleotides (CDN) (n=7). (a) Serum antibody titer of anti-ova antibodies was 
quantified via ELISA at 28- and 75-days post-immunization. Titer values were Log2 
transformed and CDNs were compared to Imiquimod for statistical significance at each 
timepoint via Unpaired t-tests (one-tailed). (b) Serum was collected from immunized mice 7 
days post-immunization and BAFF concentrations were determined via ELISA. Statistical 
significance was determined via Unpaired t-test (one-tailed). P value is indicated as follows 
(*=p<0.05). All bars and symbols indicate mean ± SEM. 
 
4. Discussion 
 As the trend to use recombinant proteins in the development and design of new 
vaccine formulations expands, there is need to develop immunization strategies that induce 
durable, protective immunity in the absence of adverse reactions [39]. Because of the low 
immunogenicity of many recombinant proteins, there is a need to include adjuvants in the 
vaccine formulation to induce an inflammatory response in order to drive higher antibody 
titers [40,41]. While safety of any adjuvant deployed for use in humans or animals is a major 
concern, patients’ perceptions of the discomfort (i.e., pain) associated with vaccines that 
employ inflammatory adjuvants (e.g., Alum, ASO4) often impacts patient willingness to 
receive a booster immunization or be immunized at all [39]. That said, these studies were 
designed to evaluate host and cellular responses induced by CDNs in comparison to TLR 
ligands in order to gain insights into functional inflammatory characteristics that would avoid 
some adverse negative aspects of inflammation and improve the outcome of an adaptive 
immune response [18]. 
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 In these studies, the differential effects of TLR agonists and CDNs on the 
outcome of antigen-specific antibody responses subsequent to vaccination were evaluated. 
The inclusion of CDNs as an adjuvant in a vaccine regimen, as compared to MPLA or 
Imiquimod, resulted in higher antibody titers at all time points after vaccination (Figure 3-1) 
suggesting that the phenotype of the inflammatory environment induced by the TLR ligands 
may have muted the magnitude of the antibody response. Therefore, studies were performed 
to elucidate the differing effects on the innate immune responses that could be responsible for 
affecting the magnitude of the observed humoral response.  
It has been shown that elevated induction of NO and ROS can inhibit B cell responses 
[10,11]. Innate immune cell derived NO in particular, has been linked to B cell death in the 
lymph node, and a suppressive effect on antibody titers [10,11]. Furthermore, levels of ROS 
have been linked to determining B cell fate (i.e., plasma cell vs class switching 
recombination in B cells) by reacting with heme and affecting its regulation of transcription 
factors (e.g., BACH2, BLIMP-1) that are critical in determining B cell phenotypes [17,42]. 
In the current study, distinct differences in the metabolic phenotype of DCs and the resultant 
levels of NO and ROS following stimulation indicated that the activation phenotype induced 
by CDN stimulation was markedly different than that induced by TLR agonists (Figure 3-2). 
Studies assessing metabolism of immune cells has inextricably linked the metabolic 
demands/profile of various immune cells to their phenotype (e.g. M1 vs M2, effector vs 
memory vs regulatory, etc.) [33,43,44]. In this regard, CDN stimulation of DCs resulted in 
the immediate upregulation of glycolysis, as well as mitochondrial respiration, resulting in a 
metabolic “double-dipping” that is indicative of a distinct phenotype in contrast to that 
induced by TLR agonist that solely upregulate glycolysis.  The CDN-induced activation 
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phenotype of DCs diverged further from that induced by TLR-ligands based on the 
production of lower levels of innate immune effector molecules (i.e. NO/ROS) and the 
differential effects on mitochondrial function at a later timepoint (e.g. 18 hours). Observed 
differences in adaptive immune responses may be the result of the contextual activation of 
APCs via innate signals linked to recognition of “infectious-nonself” activators (e.g., TLR 
signaling pathway) compared to danger/damage signals, which are not exclusively a result of 
microbial encounter (e.g., CDNs and the STING pathway) [41]. 
In addition to having direct effects on B lymphocytes, NO from inflammatory 
monocytes and monocyte derived DCs has been shown to inhibit the production of BAFF, as 
well as expression of DC costimulatory molecules [45]. To demonstrate the negative impact 
of NO on DC functions, increased expression of costimulatory molecules on BMDCs 
stimulated with TLR agonists was observed in conjunction with the use of the NOS2 
inhibitor, 1400W. As expected, the increased level of CD80 and CD86 expression on DCs 
stimulated with CDN was not affected by presence or absence of 1400W (Figure 3-4c-d).  
BAFF is a key cytokine responsible for B cell survival, maintenance of germinal 
centers, as well as for plasma cell survival, directly affecting the maintenance of antibody 
titers after vaccination. As an adjuvant that enhances B cell responses, the very low levels of 
NO produced by BMDCs stimulated with CDNs (Figure 3-3a) correlated with higher BAFF 
production as compared to the significantly lower (p ≤ 0.05) levels of BAFF induced by 
TLR-ligands in the presence of higher amounts of NO production (Figure 3-3a). In vivo, the 
heightened amounts of BAFF induced by CDNs correlated with elevated titers of anti-Ova 
antibody compared to mice immunized with Ova plus MPLA (Figure 3-5a). This effect is 
also observed in the serum BAFF concentrations of aged mice immunized with Ova plus 
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CDN when compared to aged mice immunized with Ova plus imiquimod (Figure 3-6a) and 
the significantly higher (p ≤ 0.05) antibody titers to Ova in the aged mice immunized with 
the CDN formulation (Figure 3-6b). 
Results of this study also indicated that in vivo inhibition of NOS2 derived NO with 
1400W after vaccination lead to improved antibody titers at 2 weeks post-vaccination in 
animals vaccinated with MPLA. Not unexpectedly, the administration of 1400W had no 
effect on the antibody response of mice receiving Ova plus CDNs. This suggests that even 
mice immunized with MPLA, a detoxified TLR ligand, are at a disadvantage relative to those 
receiving CDNs as a consequence of the induction of NO that contributed to lower antibody 
titers. However, at late time points (e.g., 32 weeks), mice immunized with vaccines 
incorporating either MPLA or CDNs presented with higher antigen-specific antibody titers 
when NOS2 was inhibited during the first week post-vaccination. In this situation, the 
observed benefits to mice immunized with Ova adjuvanted with CDNs are likely explained 
by the fact that CDNs, while inducing extremely low levels of NO relative to TLR agonists, 
do produce detectable levels of NO that likely have a minor effect on diminishing the 
resultant antibody response. This may be explained in part by the propensity of CDNs to 
induce interferon beta, a type 1 interferon, which have been described to inhibit the 
production of NO. This is at best a partial explanation as it has been shown that TLR 7/9 
agonists also stimulate the production of interferon alpha, another type 1 interferon, yet there 
was demonstrable production of NO in vitro (Figure 3-3 and 3-4) [10,22,23]. To achieve 
higher antibody titers post-immunization, use of an adjuvant (e.g., CDNs) that induces very 
low amounts of NO would avoid the negative impacts on the antibody response without the 
need to include a NOS2 inhibitor as part of the vaccination strategy [14,46]. 
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Recombinant subunit-based vaccine formulations will continue to require the addition 
of effective adjuvants in order to induce elevated and durable antibody responses at a given 
immunogen dose and in as few injections as possible. In this regard, it has been shown that 
multiple administrations of the DTaP vaccine to humans in the presence of inflammatory 
adjuvants induced isotype class switching such that the ratio of IgG1 to IgG4 decreased [47]. 
While IgG4 effectively neutralized toxins, this isotype does not fix complement nor does it 
effectively bind to FcRgIIIB or FcRgIIIa (i.e., a poor opsonin) [48]. Traditionally, the general 
strategy in selection of adjuvants often involved mimicking various characteristics of 
naturally-occurring infections consistent with infectious-nonself (i.e. pathogen or microbial 
associated) activation pathways [40,41]. In many situations, currently approved oil-in-water, 
TLR agonist, or aluminum salt-based adjuvants will induce efficacious immune responses 
and be effective components of vaccine formulations. However, they are not without their 
shortcomings, such as, induction of adverse, local inflammation (i.e., reactogenicity) is 
associated with oil-in-water- or alum-based adjuvants and the negative impact these 
responses have on patient compliance (i.e., avoiding booster immunization) [39]. In addition, 
these adjuvants often fail to induce optimal CD8+ T cell responses (i.e., cell-mediated 
immunity), and can be implicated in undesirable effects after subsequent re-encounter with 
antigen, such as dysfunction of T cell populations [49,50]. This is further corroborated by 
work in our laboratory that CDNs have also exhibit improved induction of vaccine-associated 
memory CD8+ T cell generation as compared to the TLR agonist CpG (data not shown). 
In conclusion, as new and more optimized vaccine formulations are identified, 
developed, and tested, the optimal immunological outcome (i.e., high titer, durable antibody 
responses, improved memory) may include/encompass a paradigm shift away from the need 
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to induce an innate immune response similar to that which occurs during infection [41]. The 
results of this study demonstrate that the choice of an adjuvant that induces a disparate 
inflammatory response from that induced by traditional MAMP-based adjuvants, that often 
induce antimicrobial effector molecules (e.g., NO, ROS), and that can result in the induction 
of effective humoral immune responses in both young and aged mice. CDNs as a vaccine 
adjuvant are an ideal candidate to induce rapid generation of high titer antibody responses 
that were durable through at least 32 weeks. In the broadest sense, individuals that may 
benefit the most from the use of CDNs in vaccine regimen would be older adults or others 
presenting as poor vaccine responders. Unlike more traditional adjuvants (e.g., alum, TLR 
ligands), these studies demonstrated that the distinct phenotype of APCs stimulated by CDNs 
contribute to enhanced antibody responses while avoiding the overt production of NO and 
mROS induced by more traditional vaccine adjuvants (e.g., TLR ligands) that may attenuate 
the resultant immune response. 
 
5. Supplemental Data 
 
Figure 3-7. Comparison of the serum antibody response in mice given a vaccine 
containing cyclic dinucleotides versus alum. Young (6-8 weeks) female C57BL/6 mice 
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were immunized subcutaneously with formulations consisting of 20 µg of the protective 
antigen (PA) from Bacillus anthracis with 20 µg CDNs, or 50 µL of BioThrax. Serum 
antibody titer of anti-PA antibodies was quantified via ELISA at (a) 4-weeks and (b) 13-
weeks post-immunization. Titer values were Log2 transformed. Individual values are symbols 
along with the group average ± SEM. n = 16 for each treatment group. Statistical significance 
was determined between treatments at each timepoint via Unpaired t-tests (two-tailed). P 
value is indicated as follows (*=p<0.05). 
 
 
Figure 3-8. Metabolic effects of CDN stimulation on J774 cells. After stimulation, 
metabolic responses of J774s to cyclic dinucleotides (CDNs) or TLR ligands was measured. 
Mitochondrial stress test (MST), (a) J774s were stimulated overnight with CDNs, Imiquimod 
(Imiq), lipopolysaccharide (LPS), CpG, or non-stimulated control in 5 mL polypropylene 
tubes. Treated J774s were seeded into seahorse plates coated with Cell-Tak at a density of 
1.7 x 105 cells per well and oxygen consumption rate (OCR) was measured. (d) Basal 
respiration, ATP production, maximal respiratory capacity, and spare capacity are calculated 
from the MST. Significance was determined via one-way ANOVA with a Sidak’s multiple 
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comparison test. Significance (p ≤ 0.05) is indicated as a comparison to control (*) or in 
comparison to CDN stimulation (#), respectively. All histograms and line graphs represent 
the group average ± SEM. Data shown is a single experimental replicate that is representative 
of two independent experiments. 
 
Figure 3-9. Induction of nitric oxide by bone marrow derived macrophages (BMMs) 
and J774 cells stimulated with cyclic dinucleotides (CDNs) or TLR ligands. Culture 
supernatants were collected at 48 hrs post-stimulation from (a) BMMs or (b) J774 cells 
treated with CDNs, CpG, Imiquimod, LPS, or medium (control) and assayed for NO 
production via Griess assay as described in Materials and Methods. All histograms represent 
the group average ± SEM. Significance was determined via one-way ANOVA with a Sidak’s 
multiple comparison test. Significance (p ≤ 0.05) is indicated as compared to control with (*) 
and as compared to CDN with (#), respectively. Data shown depict the results from a single 
experiment with n=3 for each treatment. 
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Figure 3-10. Bone marrow derived dendritic cells (BMDC) production of mitochondrial 
superoxide after stimulation. BMDCs after 48 h of stimulation with CDNs, CpG, 
Imiquimod, LPS, MPLA, or unstimulated control were assayed for mitochondrial superoxide 
production via MitoSOX staining and MFI collected via flow cytometry. All bars and 
symbols represent the group average ± SEM. Significance was determined via one-way 
ANOVA with a Sidak’s multiple comparison test. Significance (p ≤ 0.05) is indicated as 
compared to control with (*) and as compared to CDN with (#), respectively. Data shown is a 
single experimental stimulation with n=2 replicates. 
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Figure 3-11. Assessment of the murine serum antibody isotype specific response to 
ovalbumin (Ova) when adjuvanted with cyclic dinucleotides (CDNs) or TLR-ligand in 
the presence or absence of a NOS2 inhibitor. Young (6-8 weeks) female BALB/c mice 
were immunized subcutaneously with formulations consisting of 50 µg Ova alone (sOva) or 
with 20 µg of MPLA or CDN as an adjuvant. Mice were treated with MPLA or CDNs alone 
(-) or were treated intraperitoneally with the NOS2 inhibitor 1400W (+) for 7 days post-
immunization (n=6). Serum antibody titer was quantified via ELISA at (a) 2-weeks and (b) 
4-weeks post-immunization. Isotype ratios (IgG2a/IgG1) values were calculated. Individual 
values for each mouse in a given treatment group are depicted by the symbols and the group 
average ± SEM is also indicated. 
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Abstract 
 Bacillus anthracis, the causative agent of anthrax, continues to be one of the most 
prominent biological warfare and bioterrorism treats. Vaccination is likely to remain the most 
cost effective and patient friendly protective regimen for the foreseeable future. The currently 
available AVA BioThrax, while currently the best option available, has a number of 
shortcomings where improvement would lead to a more practical and effective vaccine for 
use in the case of an exposure event. Identification of more effective adjuvants and novel 
delivery platforms is necessary in order to improve not only the effectiveness of the anthrax 
vaccine, but also enhance shelf stability and ease-of-use to improve patient compliance. In 
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previous studies, cyclic dinucleotides have proven to be uniquely effective at inducing a 
beneficial inflammatory environment that leads to high titer antibodies post-vaccination 
capable of providing rapid protection against Yersinia pestis. This makes them an ideal 
adjuvant candidate for an antitoxin vaccine where rapid generation of neutralizing titers is 
critical. Polyanhydride particles have proven to be effective at adjuvanting the vaccine 
associated adaptive immune response, as well as enhancing stability of encapsulated antigen. 
Here, we evaluate the individual contributions of cyclic dinucleotides, polyanhydride 
nanoparticles, and a combination thereof to elicit high neutralizing antibody titers against the 
recombinant protective antigen from B. anthracis. 
 
1. Introduction 
Bacillus anthracis is a gram-positive, spore-forming, aerobic bacterium that is the 
causative agent of anthrax disease, observations of which date back to biblical times [1]. 
Anthrax spores are found in soil and cause disease largely amongst herbivores such as cattle, 
sheep, and goats, but can infect a wide variety of livestock and wildlife species. Humans 
have also become infected, largely by being exposed to infected animals or by working in 
facilities that handle products from infected animals (e.g. wool sorters disease). B. anthracis 
has three major routes of infection, cutaneous, gastrointestinal, and inhalation, leading to 
varied severity of disease with inhalation having the highest lethality [2]. The long-lasting, 
highly durable spores of B. anthracis are resistant to varied environmental conditions as well 
as the host immune system. The stability and dispersibility of anthrax spores contribute to 
them being a leading concern among biological warfare weapons [3–6]. 
The major virulence factors of B. anthracis infection are the anthrax toxins (AT). The 
ATs consist of lethal factor (LF), edema factor (EF), and protective antigen (PA) [7]. The 
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ATs are placed within the family of AB toxins, where the A subunit, LF and EF in this case, 
is the catalytic component within a target cell, and the PA is the B subunit that binds to the 
target cell and facilitates entry of the catalytic A subunit. The PA functions by binding to two 
potential receptors, namely, tumor endothelial marker 8 (TEM8/ANTXR1) or capillary 
morphogenesis gene-2 (CMG2/ANTXR2) on the cellular surface.  At the cell surface, PA 
undergoes proteolytic cleavage by furin or furin-like proteases [8,9] which allows PA to form 
a heptamer that is capable of binding and then, via a rachet-like mechanism, translocating LF 
and EF into the cytosol where their toxic effects occur [10,11]. 
This dependence on the activity of PA for the lethality of the ATs makes PA a logical choice 
as a target for development of a prophylactic vaccine. Neutralizing this single bacterial 
component would effectively inhibit the major disease-causing virulence attribute of B. 
anthracis infection. This has proven to be the case with the currently approved and widely 
used AVA BioThrax (AVA) vaccine. However, this vaccine formulation is not without its 
shortcomings. AVA consists of undefined components derived from culture supernatants, is 
variable in its ability to induce protective immunity across species, and requires a 6-month 
long schedule of vaccinations and regular boosters in order to be effective [12]. Studies have 
shown that the result immune response to the AVA formulation can block responses to 
functionally active regions of PA; however, much of the AVA-induced antibodies are 
skewed towards non-neutralizing epitopes [13–16]. More recently, vaccines targeting PA 
have moved toward using recombinant PA (rPA) to provide a more consistent immunogen as 
well as reduce the adverse reactogenicity associated with the use of the bacterial culture 
supernatant in AVA. However, poor shelf stability of rPA formulation has led to loss of 
rPA’s ability to induce neutralizing antibody titers [17,18]. In order to improve on AVA 
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BioThrax, and protect at-risk military personnel, workers with occupational risks of 
exposure, and to be prepared for the possibility of malicious wide-spread dispersion of B. 
anthracis spores, novel vaccine formulations are required to provide shelf and thermal 
stability to rPA, as well maintains its ability to induce high titer neutralizing antibodies up on 
vaccination. 
 Studies have evaluated the effects of polyanhydride nanoparticles to provide 
chemistry-dependent shelf stability to encapsulated antigen. The polyanhydride nanoparticles 
provided enhanced stability, as compared to alum adsorbed rPA or rPA alone, when stored at 
multiple storage temperatures. Polyanhydride nanoparticles formulated with the 
CPTEG:CPH chemistries, in particular, helped to retain the antigenicity of rPA during 
storage and the stored polyanhydride nanoparticles encapsulating rPA effectively induced 
neutralizing antibody responses in vivo [19,20]. Evaluations of the adjuvant activity of cyclic 
dinucleotides have illustrated their unique ability to induce high titer antibody responses 
upon vaccination [21–24]. Herein, we evaluate the combination of polyanhydride 
nanoparticles in conjunction with CDNs to induce high titer neutralizing antibody against the 
rPA from B. anthracis using a single dose immunization regimen. 
 
2. Materials and Methods 
2.1 Synthesis Materials 
Chemicals used for the polymer and nanoparticles synthesis: 4-p-hydroxybenzoic 
acid, tri-ethylene-glycol, 1,6- dibromohexane were obtained from Sigma Aldrich (St. Louis, 
MO); dimethyl formamide, acetic acid, acetonitrile, acetic anhydride, toluene, methylene 
chloride, pentane were purchased from Fisher Scientific (Fairlawn, NJ) and 4-p-
flourobenzonitrile was purchased from Apollo Scientific (Cheshire, UK). 
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2.2 Polymer Synthesis 
Monomers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctante (CPTEG) and 1,6-bis(p-
carboxyphenoxy) hexane (CPH) was used to synthesize the copolymer 20:80 CPTEG:CPH 
via melt polycondensation reaction as previously described [25,26]. The purity and molecular 
weight of the copolymer was characterized using 1H nuclear magnetic resonance 
spectroscopy in deuterated chloroform. The molecular weight of the copolymer was near 5.3 
kDa. 
 
2.3 Particle Synthesis 
 Polyanhydride nanoparticles encapsulating 6.8% recombinant protective antigen (PA) 
(BEI resources, Cat# NR-3780, Manassas, VA), from Bacillus anthracis, by weight were 
synthesized using 20:80 CPTEG:CPH, via flash nanoprecipitation as essentially as 
previously described [27]. Briefly, a solution of 20:80 CPTEG:CPH and PA in methylene 
chloride at a concentration of 20 mg/mL. This solution was poured into pentane at a solvent 
to anti-solvent ratio of 1:250. The nanoparticles were then collected using vacuum filtration.  
 
2.4 Animals 
 Female BALB/cAnNHsd, A/J, and C57BL/6Crl or C57BL/6NHsd mice of six to 
eight weeks of age were obtained from Jackson Laboratory (Bar Harbor, ME) or Envigo 
(Somerset, NJ), respectively. All studies involving the use of animals was carried out in 
accordance with and approval from the Iowa State University institutional animal care and 
use committee. 
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2.5 Vaccinations 
Separate groups of 6-8 week old female BALB/c, C57BL/6, or AJ mice were 
immunized subcutaneously (sc) with one of the following vaccine formulations: 1) 5 µg rPA 
encapsulated in 73.5 µg of 20:80 CPTEG:CPH (6.8% wt/wt) nanoparticles (NP), 2) 5 µg 
soluble rPA adjuvanted with 25 µg cyclic dinucleotide cdG (dithio-RP,RP-cyclic di-
guanosine monophosphate, CDN) (Aduro Biotech, Berkley, CA), 3) a combination of 5 µg 
rPA encapsulated in 73.5 µg of 20:80 CPTEG:CPH (6.8% wt/wt) nanoparticles adjuvanted 
with 25 µg CDN (NP+CDN), or 4) 5 µg soluble rPA alone (rPA). 
AVA BioThrax comparison study separate groups of mice were immunized sc with 
one of the following formulations 1) 5 µg rPA encapsulated in 73.5 µg  20:80 CPTEG:CPH 
(6.8% wt/wt) nanoparticles plus 15 µg soluble rPA (NP), 20 µg rPA adjuvanted with 20 µg 
CDN, 3) 5 µg rPA encapsulated in 73.5 µg of 20:80 CPTEG:CPH (6.8% wt/wt) 
nanoparticles plus 15 µg soluble rPA adjuvanted with 20 µg CDN, 4) 50 µL of AVA 
BioThrax (Emergent BioSolutions, Rockville, MD), or 5) PBS control. 
 
2.6 Serum antibody detection 
Vaccinated mice were bled via saphenous vein at the indicated time points post 
vaccination and serum was collected and stored at – 20 °C until used for analysis. Anti-rPA 
serum antibody titers were measured via indirect ELISA. Costar 3590 96-well EIA/RIA high 
binding plates (Corning, Corning NY) were coated with 100 µL of rPA (0.5 µg/mL in PBS) 
and incubated overnight at 4 °C. Plates were blocked using 2 % (w/v) Difco gelatin in PBS 
(0.05 M, PH 7.2) containing 0.05% Tween-20 (PBS-T) for two hours at room temperature. 
After three washes using PBS-T, serum samples were titrated across the plate using two-fold 
serial dilutions, starting at 1:200, in PBS-T containing 1% (v/v) normal goat serum.  Samples 
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were incubated overnight at 4 °C. After three washes in PBS-T, an alkaline phosphatase 
conjugated goat anti-mouse IgG (H+L) secondary detection antibody (Cat# 115-005-003, 
Jackson ImmunoResearch, West Grove, PA) was diluted 1:1000, and 100 µL was added to 
the wells and allowed to incubate at room temperature for two hours. Plates were washed 
three times with PBS-T and alkaline phosphatase substrate (Cat# BP2534, Fischer Scientific, 
Hampton, NH) was added at 1 mg/mL in buffer containing 50 mM sodium carbonate, 2 mM 
magnesium chloride, and sodium bicarbonate added to achieve a pH of 9.3. Color was 
allowed to develop for 2 hours and analyzed using the SpectraMAX 190 (Molecular Devices, 
San Jose, CA) at a wavelength of 405 nm. 
 
2.7 Peptide Array 
102 peptides (13- to 20-mers) with 10-11 overlapping amino acids (BEI resources, 
Cat# NR-527), spanning the entirity of B. anthracis PA were dissolved into DMSO at 10 
mg/mL to ensure dissolution, then diluted 10-fold in water to 1 mg/mL. Each peptide 
solution was diluted to bring the final concentration to 0.5 mg/mL in 1x print buffer (5% 
(v/v) DMSO, 137 mM NaCl, 9 mM KOH, 11.3 mM NaH2PO4). Slides were printed with 16 
arrays per slide, each containing duplicate spots for each peptide, onto Nexterion AL slides 
(Schott, Louisville, KY) using a BioRobotics MicroGRID II microarray printer (Genomic 
Solutions, Inc. Ann Arbor, MI). Following printing, slides were vacuum sealed and stored at 
-20 °C until further use. 
Microarray slides were allowed to warm to room temperature and then unsealed and 
placed on a slide warmer at 37 °C for 30 min to ensure minimal moisture presence. The 
slides were then placed immediately in a blocking solution consisting of 1 % BSA (w/v) in 
PBS-T for one hour. Slides were subsequently blocked a second time for one hour in 1 % 
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(v/v) goat serum PBS-T, then thrice washed with PBS-T and placed into a 16-well incubation 
chamber (Nexterion IC-16) to separate individual arrays. 120 µL of each serum sample was 
added at a 1:20 dilution and allowed to incubate for one hour at room temperature with gentle 
agitation. Slides were washed three times with PBS-T and biotinylated goat anti-mouse IgG 
(H+L) secondary antibody (Jackson ImmunoResearch CAT# 115-065-003) was added to 
wells at 1:1000 dilution for one hour at room temperature with gentle agitation. Slides were 
again washed thrice with PBS-T. Streptavidin Alexa Fluor 555 conjugate (Life Technologies, 
Cat# S21381, Carlsbad, CA) was added to wells at a 1:1000 dilution for 30 min at room 
temperature with gentle agitation. Slides were removed from incubation chambers, washed 
thrice with PBS-T, followed by another three washes with PBS. Slides were spun dry by 
centrifugation and read on the Scanarray 5000 laser scanner (GSI Lumonics, Bedford, MA). 
The scanned images of the microarray slides were analyzed using SoftWorRx Tracker 
v2.8 software (Applied Precision, Inc., Issaquah, WA) to detect and quantify the fluorescent 
intensity of each spot. The background-corrected fluorescence of each spot was calculated as 
the mean fluorescence intensity (MFI) of each spot minus the neighboring median 
background surrounding the spot. The mean fluorescence intensity for each peptide was 
calculated as the average of the corresponding duplicate background-corrected fluorescence 
spot values.  
 
2.8 Cell Culture 
 J774 cells were cultured and maintained in DMEM (Cat #15-013-CV, Corning) 
medium supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin, 2 mM 
glutamine, and 10 % FBS.  
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2.9 Toxin neutralization assay 
 In order to assess neutralizing activity of serum from vaccinated mice, a J774 cell-
based killing assay was used essentially as previously described [28,29]. Briefly, J774s were 
seeded into 96-well flat bottom plates (Costar, Cat #3595) at a concentration of 4 x 104 
cells/well and allowed to adhere for 18 hours. Serum samples were prepared in separate 96-
well plates by adding 100 µL of serum at a 1:200 dilution and serially diluting them across 
the plate with 2-fold dilutions. The serum samples were then incubated for 30 minutes with 
PA and lethal factor (LF) (BEI resources, Cat# NR-28544), at constant concentrations of 50 
ng/mL and 40 ng/mL respectively, then added to the prepared J774s. The cell-serum-toxin 
mixture was allowed to incubate for 4 hours after which 25 µL of a 5 mg/mL of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reagent (Invitrogen, Cat# 
M6494, Carlsbad, CA) was added. After 2 hours of incubation, supernatants were removed 
and 100 µL of dimethyl sulfoxide (Fisher Scientific, Cat# D128-500, Hampton, NH) was 
added to lyse and solubilize formazan crystals. The OD at 555 nm was measured on a 
SpectraMAX 190 and recorded for each sample. 
 
2.10 Statistical Analysis 
Data generated during anti-PA serum IgG ELISAs were log2 transformed and 
analyzed within each timepoint via one-way ANOVA with a Tukey post-test for multiple 
comparisons. Cell based toxin neutralization experiments were analyzed by calculating an 
area under the curve for each treatment group with the baseline set at the negative control. 
Difference between treatments were determined via one-way ANOVA with a Tukey post-test  
for multiple comparison. All analyses were performed using GraphPad Prism 8.0 (GraphPad 
Software, La Jolla, CA). 
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3. Results 
3.1 A co-adjuvant is required to drive high titer anti-PA antibody responses. 
 In order to achieve a more complete picture of the murine immune response induced 
by the various vaccine formulations, three strains of mice were evaluated. The C57BL/6, 
BALB/c, and A/J mice, as the standard Sterne strain B. anthracis model, were chosen to 
further our understanding in how the optimal adjuvant formulation may translate across 
strains [30,31]. The Th1 biased, poor antibody producers in the C57BL/6, Th2 biased high 
antibody producers in the BALB/c, and the A/J strain that is generates high titers in response 
to PA and is easily protected from disease [32–37]. Separate groups of mice from each of 
these three strains of mice were vaccinated with one of the following vaccine formulations: i) 
PA encapsulated in 20:80 CPTEG:CPH nanoparticles (NP), ii) PA adjuvanted with CDNs 
(CDN), iii) a combination of PA encapsulated in 20:80 CPTEG:CPH nanoparticles co-
adjuvanted with CDNs (NP+CDN), or iv) PA alone (sPA). Serum samples were collected at 
2-, 4-, and 8-weeks post-vaccination, along with an additional serum sample collected at 15-
weeks post-immunization from the AJ mice. Anti-rPA total IgG antibody titers were 
evaluated at each timepoint.  
The C57BL/6 mice exhibited lower magnitude anti-rPA titers across all timepoints as 
well as a waning titer in all treatment groups by 56 DPI. The only vaccine formulation 
capable of improving titers over sPA alone was the CDN formulation, which was observed at 
all timepoints. CDN adjuvanted titers were also significantly higher as compared to that 
induced by the NP formulation at 2-weeks, and significantly higher than that induced by 
NP+CDNs at 4-weeks post-vaccination (Figure 4-1a).   
The BALB/c mice exhibited overall higher and steadily increasing antibody responses 
over the course of the experiment as compared to C57BL/6 mice. The CDN, and NP+CDN 
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formulations were both capable of significantly improving antibody titers in the BALB/c 
mice when compared to rPA alone, and the NP formulation at all timepoints evaluated. 
CDNs also provided significantly higher anti-rpA titers two weeks post-vaccination as 
compared to the combination NP+CDN formulation (Figure 4-1b). 
The A/J mice quickly attained high anti-rPA titers and maintained them over time. 
The pattern of responsiveness to adjuvant formulation is comparable to the responses 
observed in BALB/c mice. The only formulations able to significantly improve the A/J 
antibody titers over that induced by sPA alone were CDNs and the combination of 
NP+CDNs. The 15-week timepoint does indicate the combination formulation of NP+CDNs 
had the greatest titers and maintained this elevated titer compared to rPA alone (Figure 4-1c).  
Taken together, the results using these three strains of mice with varied genetic 
propensity to produce antibody suggest that NP formulations alone are not able to provide 
any adjuvant benefit to anti-PA titers compared to that induced by rPA alone and will require 
the inclusion of a more inflammatory co-adjuvant to produce high titer antibody responses. 
The combination of NP+CDN overall provided better responses than NP alone, however, for 
the C57BL/6NHsd mice, rPA + CDNs performed the best. This suggests that the use of a 
formulation with 100 % of the immunogen encapsulated in NPs may be less than optimal to 
promote the generation of high titer antibodies, particularly at early timepoints. This could 
potentially be due to the lack of a significant bolus of antigen immediately available upon 
vaccination.   
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Figure 4-1. Multi-strain combination nanovaccine induced antibody titers against 
protective antigen.  
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Figure 4-1 Continued 
 
  (a) C57BL/6NHsd (n=6), (b) BALB/cAnNHsd (n=6), and (c) A/J (n=4) mice were 
vaccinated subcutaneously against the PA protein from B. anthracis. The formulations 
consisted of 5 µg PA encapsulated in 20:80 CPTEG:CPH nanoparticles (NP), 5 µg soluble 
PA adjuvanted with 25 µg CDNs (CDN), a combination of 5 µg PA encapsulated in 20:80 
CPTEG:CPH nanoparticles adjuvanted with 25 µg CDN (NP+CDN), or 5 µg soluble PA 
alone (sPA). Total serum IgG antibody titer to PA was quantified via ELISA at 2-weeks, 4-
weeks, and 8-weeks post-immunization. Titer values were Log2 transformed and compared at 
each timepoint for statistical significance between treatment groups via an ordinary one-way 
ANOVA with a Tukey’s multiple comparison test. P value is indicated as  
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follows for each comparison indicated (*#@&=p<0.05) (#=NP, &=CDN, @=Combo, 
*=sPA). Individual animals are shown with bars indicating mean ± SEM. 
 
3.2 CDNs induce higher titer anti-PA antibody responses as compared to AVA 
BioThrax in a single dose. 
In an effort to compare the antibody responses of our CDN and nanoparticle 
containing formulations to the commercially available AVA BioThrax formulation, a soluble 
antigen component was added to the NP groups and the overall total antigen increased to 
match that administered with CDN (i.e., group ii below). Separate groups of C57BL/6 mice 
were immunized subcutaneously with one of the following formulation: i) rPA encapsulated 
in 20:80 CPTEG:CPH NPs plus soluble rPA (NP), ii) soluble rPA adjuvanted with CDNs 
(CDN), iii) a combination of rPA encapsulated in 20:80 CPTEG:CPH nanoparticles plus 
soluble rPA adjuvanted with 20 µg of CDNs (NP+CDN), iv) the commercially available 
AVA BioThrax, or v) sham vaccinated controls (PBS). Vaccine induced total anti-rPA IgG 
antibody titers were compared between adjuvant groups. All groups that were vaccinated 
induced detectible titers as compared to sham vaccinated control mice. The CDN and 
CDN+NP groups induced significantly higher antibody titers and compared to NP alone at all 
time points evaluated. The anti-PA IgG responses induced by rPA + CDNs were also 
significantly higher at 4-weeks and beyond as compared to the AVA formulation, as well as 
at 13-weeks compared to the NP+CDN combo (Figure 4-2). 
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Figure 4-2. Combination nanovaccine comparison with commercial BioThrax 
formulation. C57BL/6Crl (n=16) mice were vaccinated subcutaneously against the PA 
protein from B. anthracis. The formulations consisted of i) 5 µg PA encapsulated in 20:80 
CPTEG:CPH nanoparticles plus 15 µg soluble PA (NP), ii) 20 µg PA adjuvanted with 20 µg 
of CDNs (CDN), iii) a combination of 5 µg PA encapsulated in 20:80 CPTEG:CPH 
nanoparticles plus 15 µg soluble PA adjuvanted with 20 µg of CDNs (NP+CDN), iv) 50 µL 
of AVA, or v) PBS control. Serum IgG antibody titer to PA was quantified via ELISA at 2-
weeks, 4-weeks, 6-weeks, 8-weeks, and 13-weeks post-immunization. Titer values were Log2 
transformed and compared at each timepoint for statistical significance between treatment 
groups via an ordinary one-way ANOVA with a Tukey’s multiple comparison test. P value is 
indicated as follows for each comparison indicated on the higher magnitude group 
(*#@&=p<0.05) (#=NP, &=CDN, @=Combo, $=AVA *=PBS). Individual animals are 
shown with bars indicating mean ± SEM. 
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3.3 Nanoparticle formulations enhance antibody responses to a linear neutralizing 
epitope of PA. 
 In order to evaluate generation of antibodies to known linear epitopes of the B. 
anthracis PA, an array of 102 overlapping peptides was printed onto microarray slides. 
C57BL/6 (from Figure 4-2) mice were immunized subcutaneously with a formulation 
consisting of rPA encapsulated in 20:80 CPTEG:CPH NPs plus soluble rPA (NP), soluble 
rPA adjuvanted with CDNs (CDN), a combination of rPA encapsulated in 20:80 
CPTEG:CPH nanoparticles plus soluble PA adjuvanted with 20 µg of CDNs (NP+CDN), the 
commercially available AVA BioThrax, or unvaccinated PBS control. Serum samples were 
collected at 4- and 13-weeks post-immunization and assayed for reactivity to a microarray of 
PA peptides (Figure 4-3a-b). While there is large variability in responses within each 
individual treatment group, vaccine formulations that contained rPA encapsulated into 
polyanhydride nanoparticles induced antibodies that recognized an epitope spanning peptides 
31 and 32 near the furin binding region. The CDN formulation, despite the overall higher 
antibody titers (Figure 4-2), did not result in any detectible antibody to this region. This 
indicates that while formulations containing NP encapsulated rPA had lower titers (Figure 4-
2), this vaccine regimen induced antibody responses that recognized differential linear 
epitopes than formulations without polyanhydride encapsulated antigens.  
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Figure 4-3. Microarray peptide walk of vaccinated mice to evaluate anti-PA reactive 
linear epitopes. 
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Figure 4-3 Continued 
 
C57BL/6 (n=16) mice were vaccinated subcutaneously against the PA protein from B. 
anthracis. The formulations consisted of 5 µg PA encapsulated in 20:80 CPTEG:CPH 
nanoparticles plus 15 µg soluble PA (NP), 20 µg PA adjuvanted with 20 µg of CDNs (CDN), 
a combination of 5 µg PA encapsulated in 20:80 CPTEG:CPH nanoparticles plus 15 µg 
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soluble PA adjuvanted with 20 µg of CDNs (NP+CDN), 50 µL of AVA, or PBS control. 
Serum samples from vaccinated mice were collected, diluted 1:20, and analyzed at (a) 4- and 
(b) 13-weeks post immunization for reactivity against 102 peptides (13- to 20-mers) with 10-
11 overlapping amino acids spanning the entire length of B. anthracis PA. 
 
3.4 CDNs and the combination of CDNs and NPs induce high magnitude PA 
neutralizing antibody titers in a single dose. 
 While evaluating linear neutralizing epitopes can provide a partial picture of vaccine 
induced antibody responses to PA, it is necessary to evaluate the overall induction of 
neutralizing antibodies. Many of these neutralizing epitopes may be conformational in nature 
and would not be detected by a series of linear peptides or an ELISA. In order to compare the 
overall neutralizing anti-PA titer, C57BL/6 (From Figure 4-2) mice were vaccinated with a 
NP formulation containing soluble and encapsulated rPA (NP), rPA adjuvanted with CDNs 
(CDN), a combination of the NP formulation containing soluble and encapsulated rPA 
adjuvanted with CDNs (NP+CDN), the AVA BioThrax vaccine, and PBS controls. Serum 
samples were collected eight weeks post-vaccination and assayed for PA neutralizing 
antibody titers in an in vitro cell based killing assay.  
All vaccinated groups were able to induce detectible levels of neutralizing antibodies; 
however, differences were observed in the magnitudes of these responses that largely 
mirrored total IgG titer. The CDN, NP+CDN, and AVA BioThrax treated groups were 
statistically improved over the control mice. The highest neutralizing titer was observed in 
mice that received the CDN containing formulations as both CDNs and NP+CDNs had 
significantly increased neutralizing titers as compared to NP alone and the alum containing 
AVA BioThrax vaccines (Figure 4-4).  
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Figure 4-4. Evaluation of protective antigen neutralizing titer in B6 mice 8 weeks after 
vaccination. C57BL/6 (n=16) mice were vaccinated subcutaneously with the PA protein 
from B. anthracis. The individual vaccine formulations consisted of i)5 µg PA encapsulated 
in 20:80 CPTEG:CPH nanoparticles plus 15 µg soluble PA (NP), ii) 20 µg PA adjuvanted 
with 20 µg of CDNs (CDN), iii) a combination of 5 µg PA encapsulated in 20:80 
CPTEG:CPH nanoparticles plus 15 µg soluble PA adjuvanted with 20 µg of CDNs 
(NP+CDN), iv) 50 µL of AVA, or v) PBS control. Neutralizing antibody titers were 
determined in the 8-week post-vaccination serum via an MTT assay. Dilution values were 
Log2 transformed and the mean area under the curve (AUC) was calculated for each 
treatment group. The AUC was compared between treatment groups via one-way ANOVA 
with a Tukey’s multiple comparison test. P value is indicated as follows (*#@&=p<0.05) 
(#=NP, &=CDN, @=Combo, $=AVA *=Control) as compared to all other groups in the 
figure legend. The upper dashed line indicates the no toxin control average OD (3.6), and the 
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lower dotted line indicates the no sample control average OD (0.7). Group averages are 
shown with error bars indicating mean ± SEM.  
 
4. Discussion 
 In this work, the ability of a combination polyanhydride nanoparticle vaccine 
platform co-adjuvanted with CDNs to induce neutralizing antibodies against the protective 
antigen of B. anthracis was evaluated. The results of this work illustrate the induction of high 
titer neutralizing antibodies with a single-dose formulation of rPA adjuvanted with CDNs, as 
well as the induction of antibodies to a linear neutralizing epitope (peptides 31-32) following 
immunization with polyanhydride nanoparticle vaccine regimen that encapsulated rPA.  The 
two vaccine regimens (CDNs and NP+CDNs) that included CDNs in the formulation 
outperformed the commercially available AVA BioThrax vaccine with respect to overall 
anti-PA titer and the induction of toxin neutralizing antibody.  
 While natural inhalation infection of humans with B. anthracis spores is rare, its 
durable spores and high lethality capable of infecting hundreds of thousands of individuals 
with a single aerosol dispersion, places B. anthracis in a position of prominence as a major 
biological warfare agent [6,38,39]. The difficulty in diagnosing anthrax, with its early onset 
of cold-like symptoms, is one of the major hurdles in managing the response to a widespread 
release event of B. anthracis spores [2,38]. If anthrax infection is identified early after 
exposure, intervention or prophylaxis with antibiotics is critical to prevent serious illness and 
death. This antibiotic regimen must be adhered to for an extended period of time as spores 
can persist in a dormant state and cause disease well after the initial exposure [39–41]. In 
order to respond to a large-scale release, a therapeutic intervention would require a large-
scale stockpile of antibiotics to be readily available at all times and would require that health 
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care workers follow up with individuals to improve upon historically poor patient compliance 
[42]. Another class of therapeutic interventions in development are toxin neutralizing 
monoclonal antibodies (mAb). Neutralizing mAbs would provide benefits over antibiotic 
usage as the two to four-week half-life of the mAbs after infusion could prove effective at 
preventing severe disease with limited treatments [43,44]. 
 While these effective treatment options are available, deploying them on any large 
scale remains a public health obstacle. Treatments including vaccination for higher risk 
populations or those who have been exposed or were potentially exposed remains the most 
cost effective and most patient friendly option available [45,46]. Even as one of the ideal 
approaches to dealing with B. anthracis as a biological agent, current vaccines targeting the 
PA have room for improvement. The major issues that need solving in next generation anti-
PA vaccines are i) reducing the number of doses required to effectively induce high 
neutralizing titer, ii) identification of adjuvants that skew responses to neutralizing epitopes 
rather than towards non-neutralizing epitopes, and iii) improving the shelf-life stability of the 
rPA protein and formulated vaccines [13–18]. 
 Encapsulation of protein payloads, including rPA, into polyanhydride particle 
formulations has illustrated the stability enhancing properties that encapsulation can provide 
during storage and upon protein release [19,47]. This enhanced stability provided by 
polyanhydride polymers would be particularly advantageous in the stockpiling and storage of 
vaccine doses to be readily distributed should the need arise. In immunization studies 
evaluating the immune response of multiple strains of mice, the NP formulation with 100 % 
of the rPA encapsulated did not result in a measurable increase in anti-PA antibody titers 
compare to that induced by rPA alone (Figure 4-1). The inclusion of CDNs as a co-adjuvant, 
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either alone or combined with the NP formulation, led to increases in anti-PA titers across all 
three strains of mice. The lone exception to this observation was injection of the NP+CDN 
combination in C57BL/6NHsd mice (Figure 4-1). At 108 days after the single dose 
immunization of A/J mice, the total anti-PA IgG response induced by the NP + CDN vaccine 
exhibited the greatest titer suggesting there is a potential immunological benefit when antigen 
is encapsulated within and released from nanoparticles over time (Figure 4-1).  While 
undefined, the data indicated that there was a decided influence of mouse genetics on the 
magnitude of the anti-PA antibody response regardless of vaccine regimen.  
 In order to improve the overall poor anti-PA IgG response in C57BL/6 mice, the 
particle containing formulations was modified to also include soluble rPA in addition to the 
encapsulated rPA. While this modified vaccine regimen did improve anti-PA titers as 
compared to the previous study (Figure 4-1a), the only group of C57BL/6 mice that 
developed significantly higher antibody titers in comparison to that induced by the Alum 
adjuvanted AVA BioThrax formulation was the CDN formulation (Figure 4-2). While total 
IgG responses are an important indicator of the effectiveness of an PA-containing vaccine 
formulation, not all PA binding antibodies are neutralizing [48]. While there are no notable 
differences in the linear epitopes recognized by antisera from mice immunized with the CDN 
alone or AVA BioThrax vaccine regimen, the formulations containing polyanhydride 
nanoparticles induced IgG to a neutralizing epitope (peptides 31,32) near the furin binding 
domain of PA (Figure 4-3). This particular stretch of amino acids is described as a linear 
neutralizing epitope near the furin binding domain and is a binding location of the 
monoclonal antibodies (mAb) from the 19D9, a neutralizing IgG, and 20G7 a non-
neutralizing IgM, hybridomas [49].This suggests that some aspect of how the PA is being 
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presented to B Cells, or through interaction with the polyanhydride particles, degraded 
polyanhydride strands, or the formulation and delivery process influenced the induction of 
antibodies to this particular domain. The pH environment can alter the propensity of PA to 
bind to its receptors and is critical in the formation of a functional pore capable of facilitating 
LF and EF entry into the cytosol [9–11,50]. The local environment associated with degrading 
polyanhydrides is likely more acidic than the tissue environment. This may be playing a role 
in altering rPA interactions with receptors, promoting aggregation, or altering its structure in 
some way as to make this epitope more available to cross-linking the BCR on B cells. 
Conformational epitopes also play a role in effective neutralization of functional PA 
activity and would not be detected [48]. In cell-based toxin neutralization assays, all tested 
vaccine formulations induced detectible neutralization of the holotoxin as evidenced by the 
inhibition of cell death. The only vaccine formulations to significantly improve neutralizing 
antibody titer, over that induced by the commercially available AVA BioThrax, were the rPA 
+ CDN, and rPA encapsulated in polyanhydride nanoparticles coadjuvanted with CDNs 
(Figure 4-4). The early high titer responses observed at 2-weeks post immunization in the 
mice receiving CDNs illustrate a potential strength for vaccination after a large-scale 
dispersal event. This propensity of CDNs to induce rapid high titers could lead to rapid 
immunity for individuals in an effected area and limit the danger of the resulting exclusion 
zone created by B. anthracis spores. Rapid generation of neutralizing antibodies would also 
have the potential of reducing the extended (60+ days) of prophylactic antibiotic treatments 
used when potential exposure has occurred.  
 In conclusion, these studies demonstrate the potential of CDNs to effectively adjuvant 
rPA to generate high titer total IgG as well as high titer neutralizing antibody responses. 
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Inclusion of polyanhydride nanoparticles with encapsulated rPA in the vaccine formulation, 
in an effort to provide potential shelf stability to the rPA led to moderate decreases in overall 
and neutralizing titer as compared to CDNs alone, however still outperformed the AVA 
BioThrax formulation. Interestingly, generally lower titer as compared to CDNs alone, NP 
containing formulations did have a positive effect on the antibody response to a linear 
neutralizing epitope suggesting a potential skewing towards a higher percentage of 
neutralizing antibodies. This may suggest that there is some advantageous protein polymer 
interaction, or other aspect of the polyanhydride particle formulation that facilitate the 
antibody response toward this particular epitope. In order to take advantage of the superior 
shelf-life stability offered by polyanhydride copolymer, further studies will be needed to 
fully elucidate the protein-polymer interactions to enhance the induction of neutralizing 
antibody titers when using a vaccine formulation with 100 % encapsulated antigen with a 
CDN co-adjuvant. 
 
5. Supplemental Data 
Table 4-1. Amino acid sequences of peptides analyzed in the PA peptide microarray. 
This table indicates the sequences used for each of the 102 overlapping peptides spanning the 
length of protective antigen from Bacillus anthracis. 
Peptide # AA Sequence 
1 MKKRKVLIPLMALSTILV  
2 PLMALSTILVSSTGNLEV  
3 LVSSTGNLEVIQAEVK  
4 NLEVIQAEVKQENRLL  
5 AEVKQENRLLNESESSSQGL  
6 NESESSSQGLLGYYFSDL  
7 GLLGYYFSDLNFQAPMVV  
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Table 4-1 Continued 
Peptide # AA Sequence 
8 DLNFQAPMVVTSSTTGDL  
9 VVTSSTTGDLSIPSSEL  
10 GDLSIPSSELENIPSENQY  
11 LENIPSENQYFQSAIW  
12 ENQYFQSAIWSGFIKVKK  
13 IWSGFIKVKKSDEYTFA  
14 VKKSDEYTFATSADNHV  
15 TFATSADNHVTMWVDDQEV  
16 VTMWVDDQEVINKASNSNK  
17 VINKASNSNKIRLEKGRL  
18 NKIRLEKGRLYQIKIQY  
19 GRLYQIKIQYQRENPTEK  
20 IQYQRENPTEKGLDFKLY  
21 TEKGLDFKLYWTDSQNKK  
22 LYWTDSQNKKEVISSDNL  
23 KKEVISSDNLQLPELKQK  
24 NLQLPELKQKSSNSRKKR  
25 KQKSSNSRKKRSTSA  
26 NSRKKRSTSAGPTVPDR  
27 TSAGPTVPDRDNDGI  
28 TVPDRDNDGIPDSLEV  
29 NDGIPDSLEVEGYTVDVK  
30 EVEGYTVDVKNKRTFL  
31 VDVKNKRTFLSPWISNIH  
32 FLSPWISNIHEKKGLTKY  
33 IHEKKGLTKYKSSPEKW  
34 TKYKSSPEKWSTASDPY  
35 EKWSTASDPYSDFEKV  
36 SDPYSDFEKVTGRIDKNV  
37 KVTGRIDKNVSPEARHPL  
38 NVSPEARHPLVAAYPIVH  
39 PLVAAYPIVHVDMENIIL  
40 VHVDMENIILSKNEDQST  
41 ILSKNEDQSTQNTDSETR  
42 STQNTDSETRTISKNTSTSR  
43 TISKNTSTSRTHTSEVH  
44 TSRTHTSEVHGNAEVHA  
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Table 4-1 Continued 
Peptide # AA Sequence 
45 EVHGNAEVHASFFDI  
46 AEVHASFFDIGGSVSAGF  
47 DIGGSVSAGFSNSNSSTV  
48 GFSNSNSSTVAIDHSLSL  
49 TVAIDHSLSLAGERTWA  
50 LSLAGERTWAETMGLNTA  
51 WAETMGLNTADTARLNA  
52 NTADTARLNANIRYV  
53 ARLNANIRYVNTGTAPIY  
54 YVNTGTAPIYNVLPTTSL  
55 IYNVLPTTSLVLGKNQTL  
56 SLVLGKNQTLATIKAK  
57 NQTLATIKAKENQLSQIL  
58 AKENQLSQILAPNNYY  
59 SQILAPNNYYPSKNLAPI  
60 YYPSKNLAPIALNAQDDF  
61 PIALNAQDDFSSTPITM  
62 DDFSSTPITMNYNQFLEL  
63 TMNYNQFLELEKTKQLRL  
64 ELEKTKQLRLDTDQVY  
65 KQLRLDTDQVYGNIATY  
66 DQVYGNIATYNFENGRVR  
67 TYNFENGRVRVDTGSNW  
68 RVRVDTGSNWSEVLPQI  
69 SNWSEVLPQIQETTARII  
70 PQIQETTARIIFNGKDL  
71 ARIIFNGKDLNLVERRIA  
72 DLNLVERRIAAVNPSDPL  
73 IAAVNPSDPLETTKPDM  
74 DPLETTKPDMTLKEALKI  
75 DMTLKEALKIAFGFNEPN  
76 KIAFGFNEPNGNLQYQGK  
77 PNGNLQYQGKDITEFDF  
78 YQGKDITEFDFNFDQQTS  
79 FDFNFDQQTSQNIKNQLA  
80 TSQNIKNQLAELNATNIY  
81 LAELNATNIYTVLDKIKL  
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Table 4-1 Continued 
Peptide # AA Sequence 
82 IYTVLDKIKLNAKMNILI  
83 KLNAKMNILIRDKRFHY  
84 ILIRDKRFHYDRNNIAV  
85 FHYDRNNIAVGADESVVK  
86 AVGADESVVKEAHREVI  
87 VVKEAHREVINSSTEGLL  
88 VINSSTEGLLLNIDKDIR  
89 LLLNIDKDIRKILSGYIV  
90 IRKILSGYIVEIEDTEGL  
91 IVEIEDTEGLKEVINDRY  
92 GLKEVINDRYDMLNISSL  
93 RYDMLNISSLRQDGKTFI  
94 SLRQDGKTFIDFKKYNDK  
95 FIDFKKYNDKLPLYI  
96 KYNDKLPLYISNPNYKV  
97 LYISNPNYKVNVYAVTK  
98 YKVNVYAVTKENTII  
99 YAVTKENTIINPSENGDT  
100 IINPSENGDTSTNGIKKI  
101 DTSTNGIKKILIFSKKGY  
102 KILIFSKKGYEIG  
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Figure 4-5. Example PA peptide microarrays. 
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Figure 4-5 Continued 
  Representative array images of vaccinated mouse serum 13 weeks post immunization 
of each of the 102 overlapping peptides spanning the length of protective antigen from 
Bacillus anthracis. The whole intact PA protein is printed near the bottom right of each array 
duplicate and indicated by a white arrow in each array. 
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CHAPTER 5.    GENERAL CONCLUSIONS 
Conclusions 
This work highlights the unique effects polyanhydride nanoparticles and cyclic 
dinucleotides have on the activation of the innate immune system. In contrast to the overtly 
inflammatory TLR ligand CpG, the relatively low grade proinflammatory effects 
polyanhydride nanoparticles activate populations of dendritic cells and upregulate 
costimulatory function to effectively induce antigen-specific CD8+ T cell memory to improve 
survival of immunized mice upon tumor challenge. STING pathway stimulation results in 
activated APCs that exhibit a distinct metabolic profile and little to no induction of NO or 
ROS. In contrast to TLR ligands, each of these adjuvant-induced phenotypes leads to a 
beneficial inflammatory environment that allows for improved adaptive immunity upon 
vaccination. 
 Polyanhydride particle formulations have previously been described to possess a 
number of pathogen-mimicking properties [1,2]. For instance, particles are readily taken up 
by phagocytic cells where they can deliver encapsulated payloads to either the endosomal or 
cytosolic compartments [3,4]. This interaction induces the activation and subsequent 
upregulation of costimulatory molecules and secretion of proinflammatory cytokines [5,6]. In 
addition to antigen delivery and APC activation, the slow degrading properties of 
polyanhydride particles allows them to persist at the site of injection. As they release their 
payload over an extended time it can mimic the persistence of antigen over the course of an 
infection [7,8]. Evaluation of safety and injection site reactogenicity reveals that the in vivo 
inflammatory response induced by polyanhydride nanoparticles is much lower than 
traditional adjuvants such as MPLA, alum, or incomplete Freund’s adjuvant [9,10].  
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Herein, we directly compared the TLR ligand CpG to 20:80 CPTEG:CPH 
nanoparticles for their ability to activate DC populations and subsequently, generation of  
memory CD8+ T cells. Dendritic cells generated from bone-marrow, as well as 
unfractionated splenic CD11c+ DCs and the subpopulation of CD8α+ DCs were evaluated for 
their responses. Despite the limited classical signs of activation, such as the induction of 
proinflammatory cytokines, nitric oxide, and induction of aerobic glycolysis, polyanhydride 
nanoparticles potently upregulated the expression of costimulatory molecules of all DC 
populations tested. In contrast, CpG was limited in its ability to upregulate costimulatory 
expression on CD8α+ DCs (Figures 2-3, 2-4, 2-9, 2-10). An analogous low inflammatory 
vaccine strategy is the use of adoptively transferred DCs, which are capable of rapidly and 
preferentially inducing high number of CD8+ memory T cells. In cases where these DCs are 
exposed to an inflammatory stimulant, such as a TLR ligand, prior to adoptive transfer, leads 
to increased CD8+ T cell effector expansion and limits the generation of memory [11]. 
Indeed, direct comparison of prophylactic vaccine formulations consisting of 20:80 
CPTEG:CPH polyanhydride nanoparticles, as compared to CpG, led to relatively greater 
induction of CD8+ T cell memory as measured by an antigen-specific tumor challenge 
(Figure 2-6). This suggests that polyanhydride nanoparticle formulations may be ideal 
candidates to induce efficacious cell-mediated immunity following the administration of a 
single dose; an outcome other adjuvant formulations have largely been unable to achieve 
without employing prime-boost strategies [12]. 
 The STING pathway is a recently discovered PRR pathway that senses nucleic acids 
in the form of cyclic dinucleotides [13]. CDNs can be released from bacteria or generated 
from double-stranded DNA, including host-DNA, via the enzyme cGAS [14,15]. The potent 
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immune stimulatory effects of CDNs are well documented as well as its effectiveness at 
inducing high titer antibodies when included in vaccine formulations [16–18]. The current 
literature suggests that CDN stimulation of the immune system results in a balanced or 
“mixed” response, suggesting STING stimulation results in a unique non-polarized 
inflammatory environment. In order to elucidate the mechanism mediating the ability of 
CDN-adjuvanted vaccines to induce such remarkably rapid and high titer antibody responses 
as compared to TLR ligands (Figure 3-1), various stimulatory effects on innate immune cells 
were compared to cells stimulated by the TLR family of receptors. 
  BMDCs stimulated with CDNs exhibited distinctly divergent acute metabolic 
responses as compared to those stimulated with TLR ligands, particular in the immediate 
upregulation of mitochondrial respiration (Figure 3-2).  Due to the close relationship between 
metabolic requirements and immunological phenotype, this is indicative of a functionally 
distinct phenotype [19]. CDN-induced activation results in the lack of production of innate 
effectors NO and mROS (Figures 3-3, 3-9, 3-10). In BMDCs and the monocyte-like J774 cell 
line, CDN-induced activation results in cellular activation without the metabolic 
commitment/shift to aerobic glycolysis (Figure 3-3, 3,8) for survival in the presence of 
antimicrobial NO. NO has also been implicated in the inhibition of B cells and resultant 
antibody responses in addition to the inhibition of pro-survival cytokines, particularly BAFF 
[20,21].  We hypothesized that this low production of NO would improve the production of 
BAFF via CDN stimulation. Indeed, inhibition of NOS2 led to reduction in NO and increased 
BAFF secretion from BMDCs stimulated with TLR ligands, comparable to the uninhibited 
CDN group (Figure 3-4). We also tested the effects of NO in vivo and found that short-term 
inhibition of NOS2 in mice receiving an MPLA adjuvanted vaccine, led to improved 
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antibody titers at 2-weeks and 32-weeks post vaccination (Figure 3-5). This leads us to 
conclude that the inflammatory environment created by CDN administration results in an 
improvement of B cell survival and subsequently, greater magnitude antibody production. 
While an antimicrobial innate inflammatory environment, as a result of vaccination, may not 
lead to major shortcomings of vaccine efficacy in young and healthy individuals, 
immunologically disadvantaged individuals, such as the aged, may be less capable of 
efficacious adaptive immunity in such an environment [22]. We hypothesized that the use of 
CDNs as a vaccine adjuvant would lead to improved vaccine-induced humoral responses in 
aged animals as compared to a TLR-targeting adjuvant. Indeed, the CDN adjuvanted 
formulation led to relatively greater concentrations of serum BAFF and higher antigen 
specific antibody titers at both 28- and 75-days post-vaccination (Figure 3-6). These results 
suggest that the potently activating, yet less pathogen-mimicking nature of CDNs and the 
STING pathway, avoid negative effects associated with innate immune responses involved in 
the clearance of microbes. These properties led to an overall more rapid induction and higher 
magnitude of adaptive immune responses to vaccine antigens. 
 Polyanhydride nanoparticles, in addition to their adjuvant capacity, are also capable 
of stabilizing encapsulated antigen [8,23,24]. This would be particularly advantageous for 
vaccine formulations containing antigens that exhibit poor shelf stability, such as PA from 
Bacillus anthracis. Previous work evaluating combination CDN and NP vaccines have 
proven successful in generating rapid immunity to Yersinia pestis [18]. In order to determine 
the ideal formulation targeting PA from B. anthracis, a PA containing combination NP and 
CDN formulation was evaluated, along with each adjuvant individually. Overall the NP 
formulation did not significantly improve antibody responses over soluble PA alone, while 
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CDNs and the combination of NPs and CDN lead to significantly higher antibody titers 
(Figure 4-1, 4-2). The single-dose CDN and combination formulations also lead to 
significantly increased titers of PA-specific neutralizing antibody as compared to the 
currently approved AVA BioThrax vaccine (Figure 4-4). This suggest that a combination 
CDN and NP vaccine would deliver both shelf stability as well single-dose high magnitude 
neutralizing antibody titers able to rapidly protect against infectious disease and avoid the 
need for long-term antibiotic treatments. 
Overall, the results of these studies suggest that the innate immune environment 
created as a consequence of vaccine adjuvants has a major impact on the magnitude and 
nature of the resultant humoral and T cell responses. The generation of antimicrobial NO and 
ROS, while critical in the innate immune-mediated clearance and control of many pathogens, 
imposes a cost on the adaptive immune response. In the formulation of recombinant subunit-
based vaccines, where no MAMPs are present and innate immune- mediated clearance is 
superfluous, identification of adjuvants and pathways that can avoid paying this adaptive cost 
of innate immune activation (i.e., a Toll too high) can result in improvements in vaccine-
induced immunity and may represent a paradigm shift in vaccine design. 
  The properties of CDNs and polyanhydride nanoparticles make them ideal 
candidates as vaccine adjuvants. This would be particularly advantageous for individuals 
who have an underlying immunological deficiency or in situations where the rapid induction 
of high titer neutralizing antibody is needed, such as an act of biological warfare where 
induction of rapid immunity is required. Lastly, as vaccine formulations are designed and 
tested, we need to consider the effects of artificially signaling through a single pathway in a 
relative vacuum. Whether it be TLR ligands generating STING inhibiting ROS or STING 
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generation of NO inhibiting type 1 interferons, natural infection results in activation of 
multiple pathways that exhibit cross-regulating properties. Care needs to be taken to ensure 
that vaccine adjuvants are not resulting in a more extreme phenotype of activation than 
occurs with natural infection. 
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